var title_f31_50_32544="Infant coarctation of the aorta and heart failure";
var content_f31_50_32544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F88511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F88511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Chest radiography of an infant with critical coarctation of the aorta and heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a chest radiograph of a newborn infant who presented with respiratory distress. Image A is a frontal radiograph of the chest demonstrating pulmonary edema caused by critical coarctation of the descending aorta, which was diagnosed by echocardiography. Image B is the lateral chest radiograph from the same patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lachlan Smith, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32544=[""].join("\n");
var outline_f31_50_32544=null;
var title_f31_50_32545="Necrobiotic nodule Low";
var content_f31_50_32545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary parenchymal involvement in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph demonstrating a necrobiotic nodule adjacent to normal lung tissue in a patient with Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32545=[""].join("\n");
var outline_f31_50_32545=null;
var title_f31_50_32546="Seborrheic dermatitis diaper area PI";
var content_f31_50_32546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile seborrheic dermatitis involving the diaper area",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32546=[""].join("\n");
var outline_f31_50_32546=null;
var title_f31_50_32547="Acid reflux (gastroesophageal reflux disease) in children and adolescents";
var content_f31_50_32547=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/50/32547/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32547/contributors\" id=\"au7273\">",
"       Harland S Winter, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/50/32547/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32547/contributors\" id=\"se4415\">",
"       William J Klish, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/50/32547/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32547/contributors\" id=\"de1276\">",
"       Alison G Hoppin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/50/32547?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Gastroesophageal reflux, also called acid reflux, occurs when the stomach contents back up (reflux) into the esophagus or mouth. Acid reflux is a normal process that occurs in healthy infants, children, and adults. Most episodes are brief and do not cause bothersome symptoms or problems.",
"    </p>",
"    <p>",
"     However, some people with acid reflux have troublesome symptoms, including heartburn, vomiting, or pain with swallowing. In this case, the problem is called gastroesophageal reflux disease (GERD). Treatments for GERD are available and can help to reduce symptoms.",
"    </p>",
"    <p>",
"     This article discusses the symptoms, causes, diagnosis, and treatment of children and adolescents with gastroesophageal reflux disease. Gastroesophageal reflux in infants and adults is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS GASTROESOPHAGEAL REFLUX?",
"     </span>",
"    </p>",
"    <p>",
"     When we eat, food is carried from the mouth to the stomach through the esophagus, a tube-like structure (",
"     <a class=\"graphic graphic_figure graphicRef52952 \" href=\"mobipreview.htm?12/55/13168\">",
"      figure 1",
"     </a>",
"     ). The esophagus is made of tissue and muscle layers that open and squeeze to move food to the stomach.",
"    </p>",
"    <p>",
"     At the lower end of the esophagus, where it joins the stomach, there is a circular ring of muscle called the lower esophageal sphincter (LES). When food reaches the LES, it relaxes so that food enters the stomach. The muscle then squeezes shut to prevent food and acid from backing up into the esophagus. However, the muscle does not always stay completely closed, allowing the stomach juices and acid to back up into the esophagus occasionally. Most of these episodes go unnoticed because the acid reflux stays in the lower esophagus.",
"    </p>",
"    <p>",
"     Acid reflux becomes gastroesophageal reflux disease (GERD) when the reflux causes irritation, injures the esophagus, or causes other problems, such as asthma. The amount of acid reflux required to cause injury varies. In general, the esophagus is more likely to be injured when:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Acid backs up into the esophagus frequently",
"      </li>",
"      <li>",
"       The stomach juices are very acidic",
"      </li>",
"      <li>",
"       The esophagus cannot clear away the acid quickly",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The treatments for GERD are designed to prevent one or all of these elements from occurring.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ACID REFLUX SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of gastroesophageal reflux depend upon the child's age. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link\">",
"      \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Preschool &mdash; Symptoms of acid reflux in preschool-age children can include:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Vomiting or feeling stomach acid or food in the throat or mouth",
"      </li>",
"      <li>",
"       Less commonly, there can be wheezing, particularly in children with asthma",
"      </li>",
"      <li>",
"       Lack of interest in eating (because of pain with eating)",
"      </li>",
"      <li>",
"       Weight loss",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Older children and adolescents &mdash; The most common symptoms of GERD in older children and adolescents include many of the symptoms listed above, plus:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Tasting stomach acid in the throat",
"      </li>",
"      <li>",
"       Nausea",
"      </li>",
"      <li>",
"       Pain or burning in the upper chest (heartburn)",
"      </li>",
"      <li>",
"       Discomfort or pain with swallowing",
"      </li>",
"      <li>",
"       Feeling that food gets stuck while swallowing",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Children who do not talk may pound their chest when they feel the heartburn. Pain usually happens after meals, may awaken the child from sleep, and may be worse with stress or when lying down. Pain can last minutes to hours.",
"    </p>",
"    <p>",
"     In all age groups, constipation can cause some of the symptoms of GERD, such as upset stomach, heartburn, and nausea. Treating constipation can relieve these problems. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=see_link\">",
"      \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ACID REFLUX DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If your child has reflux, vomiting, or abdominal pain, consult your child's doctor or nurse before giving any treatment. There are many possible reasons for these symptoms, and it is important to confirm the cause before starting a medicine.",
"    </p>",
"    <p>",
"     In children who have reflux but no reflux-related complications, the doctor or nurse might recommend lifestyle changes or a medicine before ordering tests. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Acid reflux treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If your child has reflux-related complications or other medical problems (eg, asthma, pneumonia, weight loss, persistent pain or vomiting, pain or difficulty with swallowing), testing is often needed. The type of testing depends upon your child's age and symptoms. The following is a brief description of some of the more common tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Upper endoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;An upper endoscopy is a test that might be recommended for children who have vomiting or pain or difficulty with swallowing.",
"    </p>",
"    <p>",
"     A doctor performs the test, usually in the hospital, after the child is sedated. The doctor places a small, flexible tube through the mouth into the esophagus and stomach (",
"     <a class=\"graphic graphic_figure graphicRef52952 \" href=\"mobipreview.htm?12/55/13168\">",
"      figure 1",
"     </a>",
"     ). The tube has a light and a camera. The doctor can see if there is damage and, if needed, take a sample of tissue (biopsy). The test is not painful. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      24-hour esophageal pH study",
"     </span>",
"     &nbsp;&mdash;&nbsp;A 24-hour esophageal pH study (sometimes called a pH probe) can show how frequently reflux occurs, but this information usually is not necessary to begin treatment for GERD. This test is usually reserved for children whose diagnosis is unclear after endoscopy or a trial of treatment. It may also be useful for children who continue to have reflux symptoms despite treatment.",
"    </p>",
"    <p>",
"     The test involves placing a thin tube through the nose and into the esophagus. The tube is attached to a small device that measures how much stomach acid is reaching the esophagus. The tube is left in place for 24 hours. The tube does not hurt, although some children will try to pull it out.",
"    </p>",
"    <p>",
"     While the tube is in place, you will keep a diary of your child's symptoms. A doctor will review the diary and pH results to see how frequently acid refluxes and whether there is a relationship between symptoms and reflux.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Barium swallow",
"     </span>",
"     &nbsp;&mdash;&nbsp;A barium swallow, sometimes called an upper GI series, is a test that might be recommended for children who have difficulty or pain with swallowing. A barium swallow is not usually done to confirm whether the child has reflux, but pain or difficulty swallowing can be caused by problems other than GERD, and the barium swallow is used to look for other causes.",
"    </p>",
"    <p>",
"     Barium is a substance that can be seen easily with X-ray. It can be mixed into a liquid that the child swallows. After the liquid is swallowed, the barium coats the lining of the esophagus, and a special type of X-ray (fluoroscopy) is used to see the shape and structure of the mouth, esophagus, and stomach.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ACID REFLUX TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Several treatment options are available for children with acid reflux. The \"best\" treatment depends upon your child's age, the type and severity of symptoms, and how your child responds to treatment. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link\">",
"      \"Management of gastroesophageal reflux disease in children and adolescents\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Lifestyle changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lifestyle changes, such as raising the head of the bed and losing weight, are commonly recommended for adults with GERD. These changes might be helpful for some, but not all, children with mild symptoms of acid reflux.",
"    </p>",
"    <p>",
"     Lifestyle changes are not recommended as the ONLY treatment for a child with moderate or severe symptoms of GERD. Call your child's healthcare provider before beginning any treatment for acid reflux.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid certain foods &mdash; Certain foods, including caffeine, chocolate, and peppermint, can relax the muscle in the esophagus, allowing acid to reflux. Acidic foods and drinks, including colas, orange juice, and spicy foods, may also cause more symptoms. Foods that are high in fat, such as pizza and french fries, may also increase reflux by slowing stomach emptying. These foods should be avoided if they seem to cause more symptoms, and particularly if the child is overweight.",
"      </li>",
"      <li>",
"       Raise the head of the bed 6 to 8 inches &mdash; Although some people only have heartburn for the two to three hours after meals, others wake up at night with heartburn. Raising the head of the bed might help to reduce nighttime heartburn. This raises the head and shoulders higher than the stomach, allowing gravity to prevent acid from backing up into the esophagus.",
"       <br/>",
"       <br/>",
"       You can raise the head of the bed with blocks of wood under the legs of the head of the bed or a foam wedge under the mattress. However, it is not helpful to use extra pillows; this can cause an unnatural bend in the body that increases pressure on the stomach, worsening acid reflux.",
"      </li>",
"      <li>",
"       Weight loss &mdash; In significantly overweight children, losing weight might help reduce reflux. If you are worried about your child's weight, consult a doctor or nurse for advice on helping the child to lose weight.",
"      </li>",
"      <li>",
"       Stay away from tobacco smoke &mdash; Smoking or being around tobacco smoke reduces the amount of saliva in the mouth and throat, which can worsen reflux. Saliva helps to neutralize acid. Tobacco smoke also provokes coughing, causing frequent episodes of acid reflux in the esophagus.",
"       <br/>",
"       <br/>",
"       Parents and adolescents who smoke are encouraged to quit. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Avoid lying down after eating &mdash; Lying down with a full stomach makes it easier for acid to reflux. By eating three or more hours before bedtime, you are less likely to have acid reflux while sleeping. Also avoid eating before exercising.",
"      </li>",
"      <li>",
"       Chew gum &mdash; Chewing gum can increase the amount of saliva you make, which can help to neutralize stomach acid that has entered the esophagus. However, gum is not recommended for children who are less than four years old.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are several medicines available to treat the symptoms of acid reflux. You should discuss the need for medicine with your child's doctor or nurse before beginning treatment. If your child's doctor or nurse recommends a medicine, it is usually given for a trial period (two to four weeks). After the trial period:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Your child can continue taking the medicine if reflux symptoms have improved. Children with heartburn alone are sometimes able to stop treatment after a month or two. Those with damage to the esophagus (esophagitis) may need treatment for a longer period of time.",
"      </li>",
"      <li>",
"       Your child's doctor or nurse might recommend a different medicine or further testing if symptoms have not improved or have worsened (if testing not done previously) (see",
"       <a class=\"local\" href=\"#H4\">",
"        'Acid reflux diagnosis'",
"       </a>",
"       above).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Proton pump inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Proton pump inhibitors (PPIs) are a type of medicine that works in the stomach to block acid. PPIs are more effective than other medicines in relieving symptoms, reducing acid secretion, and healing esophagitis. The most commonly used medicines in children include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Omeprazole (Prilosec, available without a prescription)",
"      </li>",
"      <li>",
"       Lansoprazole (Prevacid, available without a prescription)",
"      </li>",
"      <li>",
"       Esomeprazole (Nexium)",
"      </li>",
"      <li>",
"       Pantoprazole (Protonix)",
"      </li>",
"      <li>",
"       Rabeprazole (Aciphex)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     PPIs are usually taken by mouth (in pill or liquid form) once per day and may be taken long-term, if needed. Taking the medicine on an empty stomach (30 minutes before breakfast) will help the medicine to work best. If your child's symptoms do not improve after a two- to four-week trial of a PPI, a diagnostic test may be recommended. (See",
"     <a class=\"local\" href=\"#H5\">",
"      'Upper endoscopy'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Histamine blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;The histamine blockers also reduce acid in the stomach. However, they are somewhat less effective than PPIs. Examples of medicines available in the United States include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Ranitidine (Zantac)",
"      </li>",
"      <li>",
"       Famotidine (Pepcid)",
"      </li>",
"      <li>",
"       Cimetidine (Tagamet)",
"      </li>",
"      <li>",
"       Nizatidine (Axid)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These medicines are usually taken by mouth, in pill or liquid form, once or twice per day. Cimetidine, ranitidine, and famotidine are available without a prescription.",
"    </p>",
"    <p>",
"     If your child takes a histamine blocker first but does not get better, your child's doctor might recommend trying a PPI next. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Proton pump inhibitors'",
"     </a>",
"     above.) Histamine blockers are not usually recommended for long-term treatment of GERD because they do not work as well over time. If your child's symptoms come and go, he or she can take a histamine blocker when needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Antacids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antacids are commonly used for short-term relief of symptoms of GER in adults. However, antacids work for a very short time after each dose, so they are not very effective. Examples of antacids include Tums, Maalox, and Mylanta.",
"    </p>",
"    <p>",
"     Antacids are not recommended for infants or young children. With a doctor or nurse's approval, school-age children and adolescents can use antacids, if needed. In all age groups, antacids are not recommended for long-term treatment because they do not work as well as other medicines.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is not usually necessary in healthy children with GERD. Surgery might be an option for certain children who have serious complications of acid reflux that cannot be controlled with medicines.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Call your child's doctor or nurse if your child has one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Repeated vomiting, especially if the vomit is bloody or the child is losing weight",
"      </li>",
"      <li>",
"       Frequent heartburn or pain in the upper chest or throat",
"      </li>",
"      <li>",
"       Pain or difficulty with swallowing (eg, a sense of food getting stuck in the throat)",
"      </li>",
"      <li>",
"       New breathing problems, such as wheezing, a chronic cough, or hoarseness",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H161\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11444427\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/11/40114?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/24/43394?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/54/39778?source=see_link\">",
"      Patient information: Eosinophilic esophagitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11444458\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=see_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30441?source=see_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23657?source=see_link\">",
"      Gastroesophageal reflux in premature infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44297?source=see_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Children's Digestive Health and Nutrition Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://gerd.cdhnf.org/\">",
"        file://gerd.cdhnf.org/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/gerinchildren/index.htm\">",
"        file://digestive.niddk.nih.gov/ddiseases/pubs/gerinchildren/index.htm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.naspghan.org/wmspage.cfm?parm1=351\">",
"        www.naspghan.org/wmspage.cfm?parm1=351",
"       </a>",
"       , available in Spanish and Portuguese)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/50/32547/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/50/32547?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32547/abstract/1\">",
"      Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32547/abstract/2\">",
"      Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32547/abstract/3\">",
"      Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs 2003; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32547/abstract/4\">",
"      Diaz DM, Gibbons TE, Heiss K, et al. Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:1844.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_50_32547=[""].join("\n");
var outline_f31_50_32547=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS GASTROESOPHAGEAL REFLUX?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ACID REFLUX SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ACID REFLUX DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ACID REFLUX TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/55/13168\" title=\"figure 1\">",
"           Child upper GI anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_50_32548="Causes cervical radiculopat";
var content_f31_50_32548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Causes of cervical radiculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32548=[""].join("\n");
var outline_f31_50_32548=null;
var title_f31_50_32549="Methylergonovine: Drug information";
var content_f31_50_32549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylergonovine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/42/7845?source=see_link\">",
"    see \"Methylergonovine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F195224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Methergine&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Methergine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F195242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F195228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prevention of hemorrhage:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 0.2 mg 3-4 times daily in the puerperium for up to 7 days (maximum duration: 1 week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V.: 0.2 mg after delivery of anterior shoulder, after delivery of placenta, or during puerperium; may be repeated every 2-4 hours as needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as maleate: 0.2 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methergine&reg;: 0.2 mg/mL (1 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as maleate: 0.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Methergine&reg;: 0.2 mg [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F195202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     I.V.: Administer over &ge;60 seconds. Should not be routinely administered I.V. because of possibility of inducing sudden hypertension and cerebrovascular accident.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     I.M.: May be administered intramuscularly.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     Oral: Available in tablets for oral administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal (meets NIOSH, 2012 criteria).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F195201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of uterine atony, hemorrhage and subinvolution of the uterus following delivery of the placenta; control of uterine hemorrhage following delivery of the anterior shoulder in the second stage of labor",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Methergine&reg; may be confused with Brethine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methylergonovine and terbutaline parenteral dosage forms look similar. Due to their contrasting indications, use care when administering these agents.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Inadvertent administration of methylergonovine to newborns has been reported in place of routine medications (eg, vitamin K or hepatitis B vaccine); store methylergonovine injection separately from medications used for neonates.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F195240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Acute MI, angina pectoris, arterial spasm, atrioventricular block, bradycardia, cerebrovascular accident, chest pain, hyper-/hypotension, palpitation, tachycardia, vasospasm, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, hallucinations, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Water intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, foul taste, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg cramps, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F195205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methylergonovine or any component of the formulation; hypertension; toxemia; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F195190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Patients with coronary artery disease (CAD) or risk factors for CAD may be more likely to develop myocardial ischemia and infarction following methylergonovine-induced vasospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ergotism: Ergot alkaloid use may result in ergotism (intense vasoconstriction) resulting in peripheral vascular ischemia and possible gangrene. Ergotism is usually associated with overdosage or prolonged chronic use; do not exceed dosing guidelines and avoid prolonged administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use of other ergot alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Labor: Use with caution in the second stage of labor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sepsis: Use with caution in patients with sepsis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vascular disease: Use with caution in patients with obliterative vascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Concomitant use with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics) and ergot alkaloids has been associated with acute ergot toxicity (ergotism); concurrent use of certain ergot alkaloids (eg, ergotamine and dihydroergotamine) are not recommended by the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Not for routine I.V. administration due to risk of inducing sudden hypertensive and cerebrovascular accidents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medication errors: Inadvertent administration to newborns has been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F195238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F195195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Methylergonovine is intended for use after delivery of the infant; use is contraindicated during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F195232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4803896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     At normal doses used to control postpartum uterine bleeding, small amounts are excreted in breast milk. In one study, ten women were given a single dose of methylergonovine 0.5 mg once lactation was established. Simultaneous maternal milk and plasma samples were taken 1 and 2 hours later. Maximum milk concentrations were 410-830 pg/mL, 2-3 hours after the dose and declined to 0.2 pg/mL (median) at 5 hours. The mean M/P ratios were 0.18 (at 1 hour) and 0.17 (at 2 hours) (Vogel, 2004). Methylergonovine may decrease breast milk production. Some manufacturers do not recommend breast-feeding during therapy or for 12 hours after the last dose due to adverse reactions reported in breast-feeding infants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F195207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Methylergonovine Maleate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg/mL (1 mL): $7.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Methylergonovine Maleate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2 mg (28): $215.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15255056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F195209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Basofortina (AR, PY);",
"     </li>",
"     <li>",
"      Bledstop (ID);",
"     </li>",
"     <li>",
"      Demergin (GR);",
"     </li>",
"     <li>",
"      Expogin (TH);",
"     </li>",
"     <li>",
"      Ingagen-M (IN);",
"     </li>",
"     <li>",
"      Mem (PH);",
"     </li>",
"     <li>",
"      Mergot (PH);",
"     </li>",
"     <li>",
"      Mergotrex (PH);",
"     </li>",
"     <li>",
"      Methergin (AT, BD, BE, BF, BG, BJ, BR, CH, CI, CL, CO, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, HK, HN, IE, IL, IT, JP, KE, KP, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, PE, PH, PK, PT, RU, SC, SD, SE, SG, SK, SL, SN, TN, TR, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Metvell (ID);",
"     </li>",
"     <li>",
"      Mitrotan (BG);",
"     </li>",
"     <li>",
"      Pospargin (ID);",
"     </li>",
"     <li>",
"      Usamema (PH);",
"     </li>",
"     <li>",
"      Utergin (ID);",
"     </li>",
"     <li>",
"      Uterine (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F195189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the tone, rate and amplitude of contractions on the smooth muscles of the uterus, producing sustained contractions which shortens the third stage of labor and reduces blood loss.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F195204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oxytocic: Oral: 5-10 minutes; I.M.: 2-5 minutes; I.V.: Immediately",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: &sim;3 hours; I.M.: &sim;3 hours; I.V.: 45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 39-73 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 60%; I.M.: 78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~3 hours (range: 1.5-12.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 0.3-2 hours; I.M.: 0.2-0.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32549/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Groot AN, van Dongen PW, Vree TB, et al, &ldquo;Ergot Alkaloids. Current Status and Review of Clinical Pharmacology and Therapeutic Use Compared With Other Oxytocics in Obstetrics and Gynaecology,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(4):523-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32549/abstract-text/9806101/pubmed\" id=\"9806101\" target=\"_blank\">",
"        9806101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vogel D, Burkhardt T, Rentsch K, et al, \"Misoprostol versus Methylergometrine: Pharmacokinetics in Human Milk,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 191(6):2168-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32549/abstract-text/15592308/pubmed\" id=\"15592308\" target=\"_blank\">",
"        15592308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9637 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32549=[""].join("\n");
var outline_f31_50_32549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195224\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195225\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195242\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195228\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195200\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195186\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195202\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195249\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195201\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195251\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195240\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195205\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195190\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195238\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195195\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195197\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195208\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195232\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4803896\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195207\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255056\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195209\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195189\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195204\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/42/7845?source=related_link\">",
"      Methylergonovine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_50_32550="Granisetron: Drug information";
var content_f31_50_32550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Granisetron: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/53/1878?source=see_link\">",
"    see \"Granisetron: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/36/33349?source=see_link\">",
"    see \"Granisetron: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Granisol&trade;;",
"     </li>",
"     <li>",
"      Sancuso&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Granisetron Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Kytril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiemetic;",
"     </li>",
"     <li>",
"      Selective 5-HT",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of chemotherapy-related emesis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2 mg once daily up to 1 hour before chemotherapy or 1 mg twice daily; the first 1 mg dose should be given up to 1 hour before chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Within U.S.:",
"     </i>",
"     10 mcg/kg/dose (maximum: 1 mg/dose)  given 30 minutes prior to chemotherapy; for some drugs (eg, carboplatin, cyclophosphamide) with a later onset of emetic action, 10 mcg/kg every 12 hours may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Outside U.S.:",
"     </i>",
"     40 mcg/kg/dose (or 3 mg/dose); maximum: 9 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Breakthrough:",
"     </i>",
"     Granisetron has not been shown to be effective in terminating nausea or vomiting once it occurs and should not be used for this purpose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch: Prophylaxis of chemotherapy-related emesis: Apply 1 patch at least 24 hours prior to chemotherapy; do not apply &ge;48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemotherapy completion.  Maximum duration: Patch may be worn up to 7 days, depending on chemotherapy regimen duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of radiation therapy-associated emesis:",
"     </b>",
"     Oral: 2 mg once daily given 1 hour before radiation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postoperative nausea and vomiting (PONV):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention: 1 mg given undiluted over 30 seconds; the manufacturer recommends administration before induction of anesthesia or immediately before reversal of anesthesia.",
"     <b>",
"      Note:",
"     </b>",
"     The Society for Ambulatory Anesthesia (SAMBA) Guidelines recommend a dosage range of 0.35-1.5 mg administered at the end of surgery (Gan, 2007). However, doses &le;1 mg are generally used since doses &gt;1 mg are not more effective. Of note, 5 mcg/kg (~0.35 mg in a 70 kg adult) has been shown to be effective; doses &gt;5 mcg/kg were not more effective (Mikawa, 1997).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 1 mg given undiluted over 30 seconds",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F177454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/36/33349?source=see_link\">",
"      see \"Granisetron: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis associated with cancer chemotherapy: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F177435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F177436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kinetic studies in patients with hepatic impairment showed that total clearance was approximately halved; however, standard doses were very well tolerated, and dose adjustments are not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1 mg/mL (1 mL, 4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.1 mg/mL (1 mL); 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sancuso&reg;: 3.1 mg/24 hours (1s) [52 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total granisetron 34.3 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Granisol&trade;: 2 mg/10 mL (30 mL) [contains sodium benzoate; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Doses should be given up to 1 hour prior to initiation of chemotherapy/radiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer I.V. push over 30 seconds or as a 5- to 10-minute infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of PONV: Administer before induction of anesthesia or immediately before reversal of anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of PONV: Administer undiluted over 30 seconds.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal (Sancuso&reg;): Apply patch to clean, dry, intact skin on upper outer arm. Do not use on red, irritated, or damaged skin. Remove patch from pouch immediately before application. Do not cut patch.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F177481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, bacteriostatic water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, allopurinol, amifostine, amikacin, aminophylline, amphotericin B cholesteryl sulfate complex, ampicillin, ampicillin/sulbactam, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, dexamethasone sodium phosphate, dexmedetomidine, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, fenoldopam, filgrastim, floxuridine, fluconazole, fludarabine, fluorouracil, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, idarubicin, ifosfamide, imipenem/cilastatin, leucovorin calcium, levoleucovorin, linezolid, lorazepam, magnesium sulfate, mechlorethamine, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, minocycline, mitomycin, mitoxantrone, morphine, nalbuphine, oxaliplatin,  paclitaxel, pemetrexed, piperacillin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, propofol, ranitidine, sargramostim, sodium bicarbonate, streptozocin, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, topotecan, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, amsacrine, ceftriaxone, doxorubicin, fosaprepitant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dexamethasone sodium phosphate, methylprednisolone sodium succinate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of nausea and vomiting associated with emetogenic chemotherapy and radiation therapy; prophylaxis and treatment of postoperative nausea and vomiting (PONV)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9347706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breakthrough treatment of nausea and vomiting associated with chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2138081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Granisetron may be confused with dolasetron, ondansetron, palonosetron",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 21%; transdermal patch: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (3% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (1% to 3%), hypertension (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (10%), fever (3% to 9%), dizziness (4% to 5%), insomnia (&lt;2% to 5%), somnolence (1% to 4%), anxiety (2%), agitation (&lt;2%), CNS stimulation (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3% to 9%), abdominal pain (4% to 6%), dyspepsia (3% to 6%), taste perversion (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased (5% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Oliguria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, allergic reactions; anaphylaxis (including hypotension, dyspnea, urticaria); angina, application site reactions (transdermal patch), arrhythmias, atrial fibrillation, extrapyramidal syndrome, hot flashes, hypotension, hypersensitivity, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to granisetron or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Use with caution in patients allergic to other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonists; cross-reactivity has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ECG effects: Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists, including granisetron, have been associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QT",
"     <sub>",
"      c",
"     </sub>",
"     , JT), usually occurring 1-2 hours after I.V. administration. In general, these changes are not clinically relevant, however, when used in conjunction with other agents that prolong these intervals, arrhythmia may occur. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics), clinically relevant QT interval prolongation may occur resulting in torsade de pointes. A number of trials have shown that 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists produce QT interval prolongation to variable degrees.  Use with caution in patients at risk of QT prolongation and/or ventricular arrhythmia. Reduction in heart rate may also occur with the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists. I.V. formulations of 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists have more association with ECG interval changes, compared to oral formulations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long QT syndrome: Use with caution in patients with congenital long QT syndrome or other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], and cumulative high-dose anthracycline therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Injection contains benzyl alcohol (1 mg/mL) which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: Application site reactions, generally mild, have occurred with use; if skin reaction is severe or generalized, remove patch.  Cover patch application site with clothing to protect from natural or artificial sunlight exposure while patch is applied and for 10 days following removal; granisetron may potentially be affected by natural or artificial sunlight. Do not apply to red, irritated or damaged skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemotherapy-related emesis:",
"     <b>",
"      For chemotherapy, should be used on a scheduled basis, not on an &ldquo;as needed&rdquo; (PRN) basis,",
"     </b>",
"     since data support the use of this drug only in the prevention of nausea and vomiting (due to antineoplastic therapy) and not in the rescue of nausea and vomiting. Should only be used in the first 24-48 hours of chemotherapy. Data does not support any increased efficacy in delayed nausea and vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ileus or gastric distention: Does not stimulate gastric or intestinal peristalsis; may mask progressive ileus and/or gastric distension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Postoperative nausea/vomiting use: Routine prophylaxis for PONV is not recommended in patients where there is little expectation of nausea and vomiting postoperatively. In patients where nausea and vomiting must be avoided postoperatively, administer to all patients even when expected incidence of nausea and vomiting is low.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F177470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F177404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate or well-controlled studies in pregnant women. Teratogenic effects were not observed in animal studies. Injection (1 mg/mL strength) contains benzyl alcohol which may cross the placenta. Use only if benefit exceeds the risk.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F177441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if granisetron is excreted in breast milk. The manufacturer recommends that caution be exercised when administering granisetron to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F177416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch",
"     </b>",
"     (Sancuso Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.1 mg/24 hrs (1): $422.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Granisetron HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/mL (1 mL): $3.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $24.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/4 mL (4 mL): $84.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Granisol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/10 mL (30 mL): $84.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Granisetron HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (20): $1179.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gramet (ID);",
"     </li>",
"     <li>",
"      Granicip (IN);",
"     </li>",
"     <li>",
"      Granon (ID);",
"     </li>",
"     <li>",
"      Grantron (TW);",
"     </li>",
"     <li>",
"      Helminar (PE);",
"     </li>",
"     <li>",
"      Kanitron (KP);",
"     </li>",
"     <li>",
"      Kevatril (DE);",
"     </li>",
"     <li>",
"      Kyotil (TW);",
"     </li>",
"     <li>",
"      Kytril (AE, AR, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CN, CO, CY, CZ, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, OM, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Neosetron (BR);",
"     </li>",
"     <li>",
"      Nisetron (CO);",
"     </li>",
"     <li>",
"      Sancuso Patch (KP, PH);",
"     </li>",
"     <li>",
"      Setron (IL, TW);",
"     </li>",
"     <li>",
"      Sulingqiong (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     -receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral, I.V.: Generally up to 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Tablets and oral solution are bioequivalent; Transdermal patch: ~66% over 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2-4 L/kg; widely throughout body",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via N-demethylation, oxidation, and conjugation; some metabolites may have 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 6 hours; I.V.: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Transdermal patch: Maximum systemic concentrations: ~48 hours after application (range: 24-168 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (12% as unchanged drug, 48% to 49% as metabolites); feces (34% to 38% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andrews PL, &ldquo;The Pharmacologic Profile of Granisetron (Kytril&reg;),&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1994, 21(3 Suppl 5):3-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blower P, &ldquo;A Pharmacologic Profile of Oral Granisetron (Kytril&reg; Tablets),&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1995, 22(4 Suppl 10):3-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, &ldquo;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill D and Howell J, &ldquo;Pharmacokinetics and Bioavailability of Transdermal Granisetron After a Six-Day Application of Three Patch Sizes, Compared to 2 mg Once-Daily Oral Dose of Granisetron for Five Days,&rdquo;",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2008, 16(6):619-756 [abstract from 2008 International MASCC/ISOO Symposium].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kris MG, Hesketh PJ, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2932-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mikawa K, Takao Y, Nishina K, et al, &ldquo;Optimal Dose of Granisetron for Prophylaxis Against Postoperative Emesis After Gynecological Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(3):652-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/9296425/pubmed\" id=\"9296425\" target=\"_blank\">",
"        9296425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morrow GR, Hickok JT, and Rosenthal SN, &ldquo;Progress in Reducing Nausea and Emesis. Comparisons of Ondansetron (Zofran&reg;), Granisetron (Kytril&reg;), and Tropisetron (Navoban&reg;),&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1995, 76(3):343-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/8625113/pubmed\" id=\"8625113\" target=\"_blank\">",
"        8625113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Multinational Association of Supportive Care in Cancer (MASCC), &ldquo;Antiemetic Guidelines,&rdquo; Updated April 2010. Available at file://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2010.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navari RM and Koeller JM, &ldquo;Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonists,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(9):1276-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/12921512/pubmed\" id=\"12921512\" target=\"_blank\">",
"        12921512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmer R, &ldquo;Efficacy and Safety of Granisetron (Kytril&reg;) in Two Special Populations: Children and Adults With Impaired Hepatic Function,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1994, 21(3 Suppl 5):22-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/8042033/pubmed\" id=\"8042033\" target=\"_blank\">",
"        8042033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plosker GL and Goa KL, &ldquo;Granisetron: A Review of Its Pharmacological Properties and Therapeutic Use as an Antiemetic,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 42(5):805-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/1723376/pubmed\" id=\"1723376\" target=\"_blank\">",
"        1723376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yarker YE and McTavish D, &ldquo;Granisetron. An Update of Its Therapeutic Use in Nausea and Vomiting Induced by Antineoplastic Therapy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1994, 48(5):761-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32550/abstract-text/7530631/pubmed\" id=\"7530631\" target=\"_blank\">",
"        7530631",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8501 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-BECC0B612A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32550=[""].join("\n");
var outline_f31_50_32550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177430\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177431\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177476\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177433\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177454\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177434\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177435\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177436\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177407\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177393\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177410\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177481\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177409\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9347706\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138081\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177474\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177414\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177397\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177470\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177402\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177404\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177417\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177441\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265838\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177416\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177418\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177396\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177413\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/53/1878?source=related_link\">",
"      Granisetron: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/36/33349?source=related_link\">",
"      Granisetron: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_50_32551="Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children";
var content_f31_50_32551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32551/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32551/contributors\">",
"     Kenneth L McClain, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32551/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32551/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32551/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32551/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/50/32551/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Langerhans cell histiocytosis (LCH) of the bone, also called eosinophilic granuloma of bone, was first described in 1940 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/1\">",
"     1",
"    </a>",
"    ], and refers to a generally benign form of Langerhans cell histiocytosis localized to bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Patients may present with a solitary lesion (monostotic) or multiple sites of involvement (polyostotic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1953, eosinophilic granuloma of bone was classified along with Hand-Schuller-Christian disease (with the classic triad of exophthalmos, diabetes insipidus, and skull lesions) and Letterer-Siwe disease (lymphadenopathy, skin rash, hepatosplenomegaly, fever, anemia, and thrombocytopenia) as Histiocytosis X [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/6\">",
"     6",
"    </a>",
"    ]. Subsequently, the Langerhans cell of the skin was proposed as the underlying shared pathologic feature among these three disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, gene expression array analysis of CD207+ (langerin) histiocytes from bone lesions compared with the Langerhans cells of skin proves that these are two distinctly different cell types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/8\">",
"     8",
"    </a>",
"    ]. The pathologic cells in Langerhans cell histiocytosis are more likely derived from circulating myeloid dendritic cells.",
"   </p>",
"   <p>",
"    Under the direction of the Writing Group of the Histiocyte Society, Langerhans cell histiocytosis has been adopted as the appropriate clinicopathologic designation that encompasses and essentially replaces the previous historical terms used to classify this category of abnormal histiocyte proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/9\">",
"     9",
"    </a>",
"    ]. However, many authors continue to utilize the term eosinophilic granuloma of bone; thus, this latter terminology is still both historically and clinically relevant.",
"   </p>",
"   <p>",
"    This topic review will discuss Langerhans cell histiocytosis (LCH) of bone in children. Discussions of Langerhans cell histiocytosis involving other organs in children and adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/48/35592?source=see_link\">",
"     \"Pulmonary Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic granuloma of bone is a relatively rare disorder of unknown etiology, with an incidence of two cases per million children per year, based upon a comprehensive epidemiologic study in France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/10\">",
"     10",
"    </a>",
"    ]. It is most common in children 5 to 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Patients with single bone lesions have a mean age of 5.5 years and those with multiple bone lesions 4.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In childhood presentations prevalence is greater in males (male:female ratio of 1.1 to 2.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/11\">",
"     11",
"    </a>",
"    ]. In one large series of 211 adults with LCH, the male:female ratio was 3:1, although one may wonder about a referral bias because this report was from the armed services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/15\">",
"     15",
"    </a>",
"    ]. There are no true incidence data for LCH of the bone in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presentation of LCH with a single (monostotic) bone lesion is more common than multiple (polyostotic) bone lesions. More than one bone is involved in approximately 18 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/16\">",
"     16",
"    </a>",
"    ]. The bones most commonly affected include the skull, ribs, pelvis, long bones, mandible, and vertebrae (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64763 \" href=\"mobipreview.htm?10/40/10895\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77564 \" href=\"mobipreview.htm?27/20/27983\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ]. The skull is the most commonly involved bony site overall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/11\">",
"     11",
"    </a>",
"    ] and the frontal bone is the most common skull bone involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/12\">",
"     12",
"    </a>",
"    ]. In the spine, thoracic and lumbar vertebral involvement was found to be more common than cervical involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/10,15,18\">",
"     10,15,18",
"    </a>",
"    ], although the reverse has been reported in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28378?source=see_link\">",
"     \"Treatment of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of 47 adult patients in one study, the primary sites of bone involvement were jaw (30 percent), skull (21 percent), vertebrae (13 percent), pelvis (13 percent), extremities (17 percent), and ribs (6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/19\">",
"     19",
"    </a>",
"    ]. This distribution is in contrast to that of children, in whom the skull was the major bone area involved (40 percent), and the jaw was less often involved (8 percent).",
"   </p>",
"   <p>",
"    Clinically, patients with LCH of the bone present with painful swelling at the affected bony site with or without decreased range of motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/19\">",
"     19",
"    </a>",
"    ]. Occasionally, patients may present with pathologic fracture of an involved long bone or spinal cord compression caused by vertebral body involvement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77564 \" href=\"mobipreview.htm?27/20/27983\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Special presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of certain bones can cause problems with nearby organ systems. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with periorbital lesions often have proptosis because of the presence of a tumor mass behind the eye.",
"     </li>",
"     <li>",
"      Otitis media refractory to appropriate antibiotic coverage, accompanied by mastoid swelling, should raise suspicion of the presence of LCH involving the temporal bone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/20\">",
"       20",
"      </a>",
"      ]. Temporal bone involvement is also a rare cause of hearing loss in children and adults.",
"     </li>",
"     <li>",
"      Pain in the jaw and loose teeth may be a presenting symptom. Although bone lesions may be asymptomatic in some areas, those in the mouth are especially troublesome because of tooth loss and a high recurrence rate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=see_link&amp;anchor=H2#H2\">",
"       \"Systemic conditions associated with periodontal disease in children\", section on 'Histiocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some skull lesions are not only lytic but may have an accompanying mass that impinges on the dura. These lesions and those of the cranial facial bones or anterior or middle cranial fossae (eg, temporal, sphenoid, ethmoid, zygomatic bones) with intracranial tumor extension are part of a \"CNS-risk\" group, which has a three-fold increased risk for developing vasopressin-sensitive diabetes insipidus and an increased risk of other central nervous system disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These \"CNS risk\" lesions have high incidence (nearly 40 percent) of diabetes insipidus and subsequent other endocrine and CNS tumors or neurodegenerative syndrome when treated by only surgery, radiotherapy, or single agent chemotherapy, as opposed to approximately 20 percent when such lesions are treated with two drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'High risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Imaging characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, conventional radiographs have served as the primary imaging method used to identify and follow LCH lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17,19,22-24\">",
"     17,19,22-24",
"    </a>",
"    ]. The classic appearance of LCH in a long bone is a well-defined, lytic lesion, with or without sclerotic margins, in the diaphysis or metaphysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17,19,22\">",
"     17,19,22",
"    </a>",
"    ]. Epiphyseal lesions are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ]. Periosteal reaction may be absent, benign, or aggressive-appearing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. An associated soft tissue mass may be present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64763 \" href=\"mobipreview.htm?10/40/10895\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Skull lesions classically have a punched-out, lytic appearance. Disproportionate",
"    <span class=\"nowrap\">",
"     outer/inner",
"    </span>",
"    table involvement may lead to a beveled-edge appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17,22\">",
"     17,22",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64763 \" href=\"mobipreview.htm?10/40/10895\">",
"     image 1",
"    </a>",
"    ). A central radiodensity in a lytic lesion has been described as a button sequestrum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal lesions typically involve the vertebral body; pedicular and posterior element involvement are less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. LCH in the spine may present as a lytic lesion or, alternatively, may present with abnormal flattening of the vertebral body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. Extensive flattening of an entire vertebral body may assume a \"coin on edge\" appearance, known as vertebra plana (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77564 \" href=\"mobipreview.htm?27/20/27983\">",
"     image 2",
"    </a>",
"    ). This finding is more common in the pediatric population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/13,17\">",
"     13,17",
"    </a>",
"    ]. The intervertebral disc is normal or slightly widened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mandibular involvement can simulate the appearance of \"floating\" teeth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LCH is typically \"hot\" on radionuclide bone scans, but can be normal. Radiography and scintigraphy are complementary in this disorder, in that a radionuclide bone scan can detect some lesions poorly visualized by radiography. The extent of destructive lesions involving the orbit, mastoid, and vertebrae can be best defined by CT scanning.",
"   </p>",
"   <p>",
"    The \"activity\" of lesions may be judged subjectively by MRI or PET scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The efficacy of PET scans in localizing sites of LCH as well as other sites of LCH in 44 patients has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/27\">",
"     27",
"    </a>",
"    ]. PET scans were the most accurate method of detecting LCH lesions and showing response to therapy, except for vertebral lesions, for which MRI scans were more helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of LCH is variable and there is significant overlap between LCH and the more systemic forms of LCH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, patients with solitary LCH localized to bone (ie, monostotic LCH) have a favorable prognosis, whereas patients with multisystem involvement incur a slightly worse prognosis and a high mortality rate if they do not respond to therapy after 6 to 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/12,28\">",
"     12,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic confirmation is necessary for diagnosis, since the clinical and imaging characteristics of LCH overlap with several other disease processes, including malignancy, infection, and other benign tumors of bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate fine needle aspiration or core biopsy of a suspected lesion can yield the necessary histopathologic material for diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. According to one study, 88 percent of fine needle aspirations and 83 percent of core-needle biopsies were successful in providing adequate samples for diagnosis in solitary lesions of the axial and appendicular skeleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Histiocyte Society has established criteria necessary for the presumptive, designated, and definitive diagnosis of LCH based on immunohistochemistry and histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/5,29\">",
"     5,29",
"    </a>",
"    ]. Biopsy of suspicious lesions and staining for CD1a",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-langerin (CD207) is needed in order to confirm the diagnosis. Electron microscopy to identify Birbeck granules is performed less frequently because of time and expense. However, in the case of CNS lesions or diagnostic dilemmas, it may be a critical test for confirming the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link&amp;anchor=H452648918#H452648918\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Diagnosis and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis is suspected, imaging is necessary to classify the bone involvement into the single or multifocal category. The radiographic evaluation of LCH localized to bone includes a skeletal survey with skull films and a chest radiograph to evaluate for possible pulmonary involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ]. Additional imaging, such as CT, PET, or MRI, may be useful depending on the site of disease (eg, head and neck area, spine) and associated symptomatology (eg, myelopathy, cranial nerve abnormalities) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Imaging characteristics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The radionuclide bone scan is a complementary test to the skeletal survey, as it can detect some lesions poorly visualized by radiography, and has been proposed as a method of determining active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the skeletal survey is more accurate than bone scans, but not PET scans, in the initial characterization of LCH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/22\">",
"     22",
"    </a>",
"    ]. Suspicion for the presence of extraskeletal sites of LCH requires further imaging. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link&amp;anchor=H452648918#H452648918\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Diagnosis and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with LCH are ultimately cured of their disease, although rare individuals can have multiple recurrences over many years. One study reported a four-year event-free survival of 90 percent for patients with single bone LCH and 58 percent for those with multiple bones involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Solitary bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universally accepted protocol for the treatment of LCH localized to bone for solitary lesions that do not involve the orbit, mastoid, or temporal bones. Past strategies have utilized observation only, surgical curettage, radiation therapy, steroid injections, and chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/3,4,13\">",
"     3,4,13",
"    </a>",
"    ]. However, given the relatively favorable prognosis of localized bone LCH in non-\"CNS risk\" areas without systemic involvement, a minimally aggressive approach is most often advocated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4,13,16\">",
"     4,13,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Solitary lesions tend to be self-limited, with spontaneous regression noted in multiple studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/12,13,16,30,31\">",
"     12,13,16,30,31",
"    </a>",
"    ]. Solitary skull lesions are often treated with curettage following biopsy, with low rates of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/16\">",
"     16",
"    </a>",
"    ]. Solitary, symptomatic LCH of the long bones has been treated successfully with curettage with or without bone grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared recurrence rates between skeletally-mature and skeletally-immature patients with solitary LCH not arising in the spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 17 skeletally-immature patients treated with either biopsy and observation alone (six patients) or biopsy combined with curettage (11 patients), there were no recurrences after a minimum of three years.",
"     </li>",
"     <li>",
"      Twenty-six percent of skeletally-mature patients had recurrence following biopsy, curettage, and bone grafting, suggesting a more aggressive treatment protocol may be necessary in skeletally-mature patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intralesional injection of glucocorticoids at time of biopsy has been proposed as an effective and minimally invasive treatment of solitary lesions in the axial and appendicular skeleton, with the additional benefits of immediate pain control and improved range of motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LCH lesions of the spine, such as vertebra plana, do not involve the endochondral ossification centers. Therefore, reconstitution of some degree of vertebral body height is possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/3,4,13,16\">",
"     3,4,13,16",
"    </a>",
"    ]. Treatment often consists of bed rest and external immobilization with a rigid orthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. In such cases, MRI imaging four weeks after immobilization has been recommended in order to assess for resolution or progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with neurologic symptoms or unstable lesions, surgical fixation may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. In one pediatric case, a spinal lesion was treated with posterior fusion because the patient was unlikely to comply with activity restrictions and immobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     High risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of presentations indicate that the patient is at high risk for recurrence, complications, or multisystem disease. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skeletally mature patients",
"     </li>",
"     <li>",
"      Involvement of more than one bone",
"     </li>",
"     <li>",
"      Involvement of \"Central nervous system (CNS)-risk\" bones",
"     </li>",
"     <li>",
"      Multisystem involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These special sites have been designated because of the recognition that patients with multifocal bone disease and those patients with disease at the base of the skull need to have systemic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , not just local therapy or single-drug administration. Such treatments are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28378?source=see_link&amp;anchor=H6872370#H6872370\">",
"     \"Treatment of Langerhans cell histiocytosis\", section on 'Adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with CNS risk lesions and those with multifocal bone disease should be treated with six months of velban and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    on the LCH-III protocol (Group 3). New treatment recommendations will be published with results of the LCH-III trial, which concluded in 2008. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28378?source=see_link&amp;anchor=H42641525#H42641525\">",
"     \"Treatment of Langerhans cell histiocytosis\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is generally reserved only for lesions affecting vital structures and for lesions progressing following more conservative treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/13\">",
"     13",
"    </a>",
"    ]. As an example, low dose radiation therapy has been advocated in cases of skull lesion relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/16\">",
"     16",
"    </a>",
"    ]. The typical dose range is 6 to 12 Gy delivered at 2 Gy per fraction.",
"   </p>",
"   <p>",
"    Low dose radiation therapy has also been advocated for symptomatic lesions which are persistent or recurrent following chemotherapy at sites where radiation might present less risk than curettage (eg, involvement of the spine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/2\">",
"     2",
"    </a>",
"    ]. However, radiation can damage remaining endochondral ossification centers and inhibit vertebral reconstruction, along with other secondary effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ongoing area of research in the development of innovative treatments for LCH includes immunophenotypic analysis of Langerhans cell activity. Langerhans cells within bone (LCH) have been identified as immature and poorly immunogenic. Thus, the development of drugs that enhance maturation of Langerhans cells may be beneficial in the treatment of LCH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/32\">",
"     32",
"    </a>",
"    ]. Results from gene array studies may lead to new potential therapeutic targets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CONTACT INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international directory of affiliated organizations dealing with the histiocytic disorders can be found at",
"    <a class=\"external\" href=\"file://www.histio.org/\">",
"     www.histio.org",
"    </a>",
"    . The website for the Histiocytosis Association of America can be found at",
"    <a class=\"external\" href=\"file://www.histio.org/us/assn\">",
"     www.histio.org/us/assn",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Treatment protocols for Langerhans cell histiocytosis will be available only to investigators who have successfully submitted the LCH-IV trial to their local IRB. A series of treatment recommendations can be found on the Histiocyte Society website:",
"    <a class=\"external\" href=\"file://www.histiocytesociety.org/\">",
"     www.histiocytesociety.org",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32551/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Langerhans cell histiocytosis (LCH), also called eosinophilic granuloma of bone, is a relatively rare disorder of unknown etiology, probably arising from circulating myeloid dendritic cells. It is most common in children 5 to 10 years of age. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Disease presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presentation of LCH with a single bone lesion is more common than multiple bone lesions. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bones most commonly affected in children include the skull, ribs, pelvis, long bones, mandible, and vertebrae.",
"     </li>",
"     <li>",
"      Patients with LCH present with painful swelling at the affected bony site with or without decreased range of motion. Pathologic fracture or spinal cord compression may also occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other presentations include the following. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Special presentations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proptosis due to a tumor mass behind the eye",
"     </li>",
"     <li>",
"      Pain in the jaw and loose teeth",
"     </li>",
"     <li>",
"      Refractory otitis media or hearing loss due to LCH involving the temporal bone",
"     </li>",
"     <li>",
"      Some skull lesions may have an accompanying mass that impinges on the dura, with a risk for diabetes insipidus and other CNS disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21048?source=see_link\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'High risk patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy of suspicious lesions and staining for CD1a",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-langerin (CD207) is needed in order to confirm the diagnosis of LCH. Electron microscopy to identify Birbeck granules is performed less frequently. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Solitary lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no universally accepted protocol for the treatment of solitary LCH lesions that do not involve the orbit, mastoid, or temporal bones. Past strategies have utilized observation only, surgical curettage, radiation therapy, steroid injections, and chemotherapy",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     High risk lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions involving the orbit, mastoid, or temporal bones (\"CNS risk\" lesions) and multifocal bone lesions do better when treated with two drugs (eg, the LCH-III trial involving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for six months), the standard of care for children, rather than with surgery, radiotherapy, or single agent chemotherapy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Contact information'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/1\">",
"      Lichtenstein L, Jeffe HL. Eosinophilic granuloma of bone: With report of a case. Am J Pathol 1940; 16:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/2\">",
"      Ghanem I, Tolo VT, D'Ambra P, Malogalowkin MH. Langerhans cell histiocytosis of bone in children and adolescents. J Pediatr Orthop 2003; 23:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/3\">",
"      Plasschaert F, Craig C, Bell R, et al. Eosinophilic granuloma. A different behaviour in children than in adults. J Bone Joint Surg Br 2002; 84:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/4\">",
"      Yasko AW, Fanning CV, Ayala AG, et al. Percutaneous techniques for the diagnosis and treatment of localized Langerhans-cell histiocytosis (eosinophilic granuloma of bone). J Bone Joint Surg Am 1998; 80:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/5\">",
"      Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/6\">",
"      LICHTENSTEIN L. Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Sch&uuml;ller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol 1953; 56:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/7\">",
"      Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine 1973; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/8\">",
"      Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184:4557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/9\">",
"      Histiocytosis syndrome in children. Writing Group of the Histiocyte Society. Lancet 1987; 24:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/10\">",
"      Guyot-Goubin A, Donadieu J, Barkaoui M, et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer 2008; 51:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/11\">",
"      Malpas JS. Langerhans cell histiocytosis in adults. Hematol Oncol Clin North Am 1998; 12:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/12\">",
"      Cochrane LA, Prince M, Clarke K. Langerhans' cell histiocytosis in the paediatric population: presentation and treatment of head and neck manifestations. J Otolaryngol 2003; 32:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/13\">",
"      Bertram C, Madert J, Eggers C. Eosinophilic granuloma of the cervical spine. Spine (Phila Pa 1976) 2002; 27:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/14\">",
"      Jubran RF, Marachelian A, Dorey F, Malogolowkin M. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer 2005; 45:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/15\">",
"      Islinger RB, Kuklo TR, Owens BD, et al. Langerhans' cell histiocytosis in patients older than 21 years. Clin Orthop Relat Res 2000; :231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/16\">",
"      Karagoz Guzey F, Bas NS, Emel E, et al. Polyostotic monosystemic calvarial and spinal langerhans' cell histiocytosis treated by surgery and chemotherapy. Pediatr Neurosurg 2003; 38:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/17\">",
"      Meyer JS, De Camargo B. The role of radiology in the diagnosis and follow-up of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/18\">",
"      Jiang L, Liu ZJ, Liu XG, et al. Langerhans cell histiocytosis of the cervical spine: a single Chinese institution experience with thirty cases. Spine (Phila Pa 1976) 2010; 35:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/19\">",
"      Baumgartner I, von Hochstetter A, Baumert B, et al. Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol 1997; 28:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/20\">",
"      Bayazit Y, Sirikci A, Bayaram M, et al. Eosinophilic granuloma of the temporal bone. Auris Nasus Larynx 2001; 28:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/21\">",
"      Grois N, P&ouml;tschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/22\">",
"      Howarth DM, Mullan BP, Wiseman GA, et al. Bone scintigraphy evaluated in diagnosing and staging Langerhans' cell histiocytosis and related disorders. J Nucl Med 1996; 37:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/23\">",
"      Aric&ograve; M, Egeler RM. Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/24\">",
"      Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol 2005; 35:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/25\">",
"      Binkovitz LA, Olshefski RS, Adler BH. Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings. Pediatr Radiol 2003; 33:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/26\">",
"      De Schepper AM, Ramon F, Van Marck E. MR imaging of eosinophilic granuloma: report of 11 cases. Skeletal Radiol 1993; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/27\">",
"      Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009; 52:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/28\">",
"      Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol 1999; 16:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/29\">",
"      Terracciano L, Kocher T, Cathomas G, et al. Langerhans cell histiocytosis of the stomach with atypical morphological features. Pathol Int 1999; 49:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/30\">",
"      Oliveira M, Steinbok P, Wu J, et al. Spontaneous resolution of calvarial eosinophilic granuloma in children. Pediatr Neurosurg 2003; 38:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/31\">",
"      Yanagawa T, Watanabe H, Shinozaki T, et al. The natural history of disappearing bone tumours and tumour-like conditions. Clin Radiol 2001; 56:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32551/abstract/32\">",
"      Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001; 97:1241.",
"     </a>",
"    </li>",
"    <li>",
"     www.histiocytesociety.org (Accessed on March 31, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8369 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32551=[""].join("\n");
var outline_f31_50_32551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Special presentations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Imaging characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Solitary bone lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      High risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CONTACT INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Disease presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Solitary lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - High risk lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8369\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8369|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/40/10895\" title=\"diagnostic image 1\">",
"      LCH skull",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/20/27983\" title=\"diagnostic image 2\">",
"      LCH spine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/60/8137?source=related_link\">",
"      Systemic conditions associated with periodontal disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/45/28378?source=related_link\">",
"      Treatment of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_50_32552="Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma";
var content_f31_50_32552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Daniel H Sterman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Leslie A Litzky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Larry R Kaiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Steven M Albelda, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32552/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/50/32552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant mesothelioma is an insidious neoplasm with a very poor prognosis. It arises from mesothelial surfaces of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium.",
"   </p>",
"   <p>",
"    The clinical presentation, evaluation, and staging of malignant pleural mesothelioma will be reviewed here. Other related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7622?source=see_link\">",
"       \"Epidemiology of malignant mesothelioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29204?source=see_link\">",
"       \"Pathology of malignant pleural mesothelioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=see_link\">",
"       \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link\">",
"       \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=see_link\">",
"       \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with malignant pleural mesothelioma present with the gradual onset of pulmonary symptoms, which generally are present only when disease is relatively advanced. Typical findings on chest imaging combined with a history of asbestos exposure may raise the suspicion of a malignant mesothelioma. In rare cases, patients may present with a paraneoplastic syndrome or have symptoms from a paraneoplastic syndrome in combination with their pulmonary disease manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16617531\">",
"    <span class=\"h2\">",
"     Clinical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant pleural mesothelioma usually presents with nonspecific pulmonary symptoms (chest pain, dyspnea, cough) due to the presence of extensive intrathoracic disease. Symptoms may be present for months or longer prior to diagnosis. Systemic symptoms such as fatigue and weight loss may also be present, particularly in patients with advanced disease.",
"   </p>",
"   <p>",
"    Common physical findings at the time of diagnosis generally are due to the pulmonary disease and include unilateral dullness to percussion at the lung base, decreased air movement on the side of involvement, and asymmetric chest wall expansion during respiration. Palpable chest wall masses and scoliosis toward the side of the malignancy may be seen with advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16617524\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest imaging is generally done as part of the initial symptom evaluation. In rare cases, the diagnosis is suggested by abnormal findings on chest imaging in the absence of symptoms.",
"   </p>",
"   <p>",
"    Although imaging cannot establish the diagnosis, it may provide substantial evidence suggesting the presence of mesothelioma. Typically, chest x-rays show a unilateral pleural abnormality with a large, unilateral pleural effusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52053 \" href=\"mobipreview.htm?19/52/20288\">",
"     image 1A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixty percent of patients have right-sided lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mesothelioma occasionally presents with a pleural mass or rind or diffuse pleural thickening in the absence of a pleural effusion.",
"     </li>",
"     <li>",
"      Only 20 percent of patients with pleural mesothelioma have radiographic signs of asbestosis (such as bibasilar interstitial fibrosis), although most will have evidence of pleural plaques",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcifications.",
"     </li>",
"     <li>",
"      Ipsilateral mediastinal shift can be seen secondary to encasement of lung by a thick rind of tumor.",
"     </li>",
"     <li>",
"      Most patients have significant unilateral loss of lung volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased uptake of fluorodeoxyglucose (FDG) by PET may be a useful marker to distinguish malignant pleural mesothelioma from benign mesothelioma disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. PET and integrated PET-CT may also have a role in assessing mediastinal lymph nodes. (See",
"    <a class=\"local\" href=\"#H16616577\">",
"     'PET and integrated PET-CT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example, in one series, FDG uptake was increased in 22 of 24 patients (91 percent) with mesothelioma, but none of four with benign pleural disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, in a second report increased FDG uptake was seen in 15 of 17 mesothelioma patients, compared to 0 of 14 patients with benign pleural disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other thoracic imaging approaches (CT, MRI,",
"    <span class=\"nowrap\">",
"     PET/CT)",
"    </span>",
"    may be useful in further characterizing the extent and nature of disease involvement, but these are primarily useful in determining whether or not the patient is a candidate for surgical resection. (See",
"    <a class=\"local\" href=\"#H16615949\">",
"     'Staging evaluaton'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568139496\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biomarkers are selectively elevated in patients with mesothelioma. However, these do not have an established role, either in establishing the initial diagnosis or for monitoring response to therapy. Biomarkers of interest include fibulin-3, mesothelin, and osteopontin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568139503\">",
"    <span class=\"h3\">",
"     Fibulin-3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibulin-3 is an extracellular glycoprotein that is encoded by the epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/4\">",
"     4",
"    </a>",
"    ]. Initial studies from three sites found that elevated levels of fibulin-3 in the plasma had a high sensitivity and specificity (97 and 96 percent, respectively) in distinguishing patients with pleural mesothelioma from those with a history of asbestos exposure but without mesothelioma and from those with other malignancies or benign causes of pleural effusion. Levels of fibulin-3 fell in patients who underwent surgical resection.",
"   </p>",
"   <p>",
"    Additional studies assessing the role of plasma fibulin-3 measurement will be required to determine the role of fibulin-3 as a biomarker for early diagnosis and for monitoring patients who have undergone therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568139510\">",
"    <span class=\"h3\">",
"     Mesothelin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesothelin is a glycoprotein that is expressed on the surface of normal mesothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/5\">",
"     5",
"    </a>",
"    ] and is highly overexpressed in malignant mesothelioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/6\">",
"     6",
"    </a>",
"    ]. Soluble mesothelin-related peptides (SMRPs) are believed to be either cleaved peptide fragments of mesothelin, or abnormal variants of mesothelin that are unable to bind to membranes and are found in the serum.",
"   </p>",
"   <p>",
"    Multiple studies have observed that SMRPs are elevated in patients with mesothelioma. A meta-analysis of 16 diagnostic studies found that the sensitivity ranged from 19 to 68 percent, depending upon the specific criterion for positivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/7\">",
"     7",
"    </a>",
"    ]. In patients with stage I or II disease, the sensitivity was only 32 percent when a specificity criterion of 95 percent was used. Furthermore, the potential utility of serum SMRPs is limited to patients with epithelioid or mixed mesotheliomas and not those with sarcomatoid lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29204?source=see_link\">",
"     \"Pathology of malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SMRPs have also been measured in pleural fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In a retrospective study of 52 patients with malignant mesothelioma, the assay had a sensitivity of 67 percent with a specificity of 98 percent in 84 patients with benign pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/9\">",
"     9",
"    </a>",
"    ]. In both pleural and peritoneal fluids, elevated levels of SMRPs were observed with other malignancies, particularly ovarian and pancreatic cancer.",
"   </p>",
"   <p>",
"    In patients presenting with a suspected mesothelioma, elevated SMRPs in serum, pleural effusion, or ascites fluid cannot replace a histologic diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/11\">",
"     11",
"    </a>",
"    ]. Measurement of SMRPs is commercially available (Mesomark assay) but is indicated only for monitoring patients in whom the diagnosis has already been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1568139517\">",
"    <span class=\"h3\">",
"     Osteopontin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopontin is a glycoprotein that mediates cell-matrix interactions and is overexpressed in several types of cancer. In a study of 190 patients, osteopontin levels were higher in patients with malignant mesothelioma (133",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    than in patients with asbestos-related nonmalignant pleural disease (30",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    or no prior asbestos exposure (20",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/12\">",
"     12",
"    </a>",
"    ]. Pleural fluid osteopontin levels may also be helpful in distinguishing malignant mesothelioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. At least one study suggests that osteopontin had a lower diagnostic accuracy than mesothelin in patients with suspected malignant mesothelioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539890722\">",
"    <span class=\"h2\">",
"     Paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant mesothelioma has been associated with a wide range of paraneoplastic syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/16-19\">",
"     16-19",
"    </a>",
"    ], although these are generally seen in the context of advanced pulmonary disease. Reported paraneoplastic conditions include disseminated intravascular coagulation, migratory thrombophlebitis, thrombocytosis, hypoglycemia, neurologic disorders, renal disease, and hypercalcemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of malignant pleural mesothelioma requires histopathologic examination of tissue, and cannot be based exclusively on clinical or imaging findings even when these are combined with a history of asbestos exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29204?source=see_link\">",
"     \"Pathology of malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of malignant pleural mesothelioma includes both benign and malignant processes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory reactions, such as chronic organized empyema, can often mimic the dense parietal and visceral pleural thickening along with a large pleural effusion that is characteristic of mesothelioma.",
"     </li>",
"     <li>",
"      Epithelial mesotheliomas can be extremely difficult to distinguish grossly and histologically from involvement of the pleura with metastatic tumor from another site. Other possible primary sources include but are not limited to the lung, breast, stomach, kidney, ovary, thymus, and prostate.",
"     </li>",
"     <li>",
"      Sarcoma (eg, fibrosarcoma) and malignant fibrous histiocytoma can present in similar fashion and infiltrate like sarcomatous mesotheliomas.",
"     </li>",
"     <li>",
"      The mixed-cellular type of mesothelioma can histologically resemble sarcomatoid carcinoma and synovial sarcoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tissue diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with a significant pleural effusion, thoracentesis for cytology and closed pleural biopsy is generally the initial procedure and may be sufficient to establish the diagnosis. However, this approach may not provide enough tissue to establish the diagnosis of malignancy and to distinguish mesothelioma from other tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29204?source=see_link\">",
"     \"Pathology of malignant pleural mesothelioma\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    However, establishing a tissue diagnosis and characterizing the mesothelioma can be difficult. Negative results from thoracentesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural biopsy do not exclude the diagnosis of mesothelioma. If the initial thoracentesis and pleural biopsy is nondiagnostic, surgical intervention (via video thoracoscopic biopsy or open thoracotomy) has a higher diagnostic yield. Concurrent bronchoscopy may be helpful in distinguishing mesothelioma from metastatic adenocarcinoma of the lung, as endobronchial lesions are rarely seen in mesothelioma.",
"   </p>",
"   <p>",
"    The difficulties in establishing a diagnosis of mesothelioma are illustrated by a study of 188 consecutive patients evaluated between 1973 and 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/20\">",
"     20",
"    </a>",
"    ]. Thoracentesis and pleural fluid cytology yielded a diagnosis in 26 percent of cases, and thoracentesis plus closed pleural biopsy was diagnostic in 39 percent of cases. In contrast, video-assisted thoracoscopic (VATS) biopsy was diagnostic in 98 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41414?source=see_link\">",
"     \"An overview of medical thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 10 percent of patients who undergo an invasive diagnostic procedure for mesothelioma seed the biopsy site with tumor cells and later develop a chest wall recurrence. This complication can potentially be avoided by administering prophylactic radiation therapy to the surgical scar or thoracentesis site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16615464\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate staging system is needed to guide the choice of therapy for patients with mesothelioma and ultimately to assess the results of treatment with different modalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16615788\">",
"    <span class=\"h2\">",
"     Staging systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used staging system is the tumor (T), node (N), metastasis (M) staging system that has been adopted by both the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/22\">",
"     22",
"    </a>",
"    ]. The 2010 version of the TNM staging system is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef81665 \" href=\"mobipreview.htm?43/19/44349\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the TNM staging system, stages I and II disease have pleural involvement, potentially including diaphragmatic muscle or pulmonary parenchyma, but without involvement of lymph nodes, distant metastases, or locally advanced, unresectable disease. Stage III mesothelioma includes those cases with regional lymph node involvement. Stage IV includes those with locally advanced unresectable disease, contralateral lymph node involvement, supraclavicular lymph node involvement, or distant metastases.",
"   </p>",
"   <p>",
"    Other staging systems have been developed and are used at some centers. As an example, the Brigham staging system is a modification of the older Butchart system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/23\">",
"     23",
"    </a>",
"    ]. Involvement of hilar, ipsilateral, and midline mediastinal lymph nodes categorizes a patient as stage II. In addition, the presence of positive surgical margins also qualifies for classification as stage II. Invasion of chest wall, mediastinum, heart, esophagus or contralateral structures upstages a patient to stage III as does extrapleural nodal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16615949\">",
"    <span class=\"h2\">",
"     Staging evaluaton",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical staging of malignant mesothelioma is performed radiographically in patients with potentially resectable malignant mesothelioma. Although radiographic staging evaluation is warranted, accurate staging is only possible at the time of operation (",
"    <a class=\"graphic graphic_figure graphicRef87269 \" href=\"mobipreview.htm?29/63/30718\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16616892\">",
"    <span class=\"h3\">",
"     Chest CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT is important in detecting invasion of the chest wall, ribs, and mediastinal structures structures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52053 graphicRef70651 \" href=\"mobipreview.htm?40/60/41925\">",
"     image 1A-B",
"    </a>",
"    ). Loss of normal fat planes, gross extension into mediastinal fat, and tumor surrounding more than 50 percent of a mediastinal structure all suggest tumor invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the accuracy of chest CT for detecting intrathoracic lymph nodes involvement is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16616570\">",
"    <span class=\"h3\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selected patients with potentially resectable disease, MR imaging may be useful to define the local extent of disease. Coronal MRI in particular may identify extension of pleural mesothelioma through the diaphragm into the peritoneal cavity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66436 graphicRef78690 \" href=\"mobipreview.htm?9/26/9637\">",
"     image 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16616577\">",
"    <span class=\"h3\">",
"     PET and integrated PET-CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET using 18-fluorodeoxyglucose (FDG) has advantages for detecting extrathoracic disease. However, there are significant numbers of false positive and false negatives when PET is used alone for assessment of mediastinal lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/2,28\">",
"     2,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integrated PET-CT imaging appears to be the most reliable imaging modality for initial assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The results with this approach are illustrated by three single institution series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 42 consecutive patients without evidence of T4 or M1 disease based upon CT were assessed with PET-CT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/29\">",
"       29",
"      </a>",
"      ]. In 12 cases (29 percent), patients were reclassified as inoperable, based upon the presence of a T4 lesion or distant metastasis (29 and 14 percent, respectively).",
"     </li>",
"     <li>",
"      In another series, 54 patients with potentially resectable mesothelioma (stage",
"      <span class=\"nowrap\">",
"       II/III)",
"      </span>",
"      were assessed with PET-CT. Surgery was used to confirm the imaging findings in 52 cases, and two patients with distant metastases were followed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      was significantly more accurate than CT, MRI, or PET alone in both stage II and stage III disease.",
"     </li>",
"     <li>",
"      In a third series, PET-CT was compared with CT in 35 patients with mesothelioma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/31\">",
"       31",
"      </a>",
"      ]. Surgical resection was excluded in 14 of 35 cases (40 percent) based upon the PET-CT findings, most frequently because of an increase in staging of the primary tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16616377\">",
"    <span class=\"h3\">",
"     Surgical staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;If extrapleural pneumonectomy (EPP) is still being considered after imaging studies, extended surgical staging has been advocated. In a series of 118 consecutive patients, surgical staging included laparoscopy with peritoneal lavage to detect subdiaphragmatic involvement, followed by mediastinoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/32\">",
"     32",
"    </a>",
"    ]. This approach was able to avoid an inappropriate intervention in 16 patients (14 percent).",
"   </p>",
"   <p>",
"    Mediastinoscopy plays an increasingly important role in the diagnosis and staging of mesothelioma, as recent studies have documented a significant negative prognostic implication of mediastinal nodal invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16615795\">",
"    <span class=\"h2\">",
"     Stage and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major limitation of all of the staging systems is the difficulty in assessing the extent of disease prior to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16617040\">",
"    <span class=\"h3\">",
"     IASLC IMIG database",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to improve upon the current TNM system, the International Association for the Study of Lung Cancer (IASLC) and the International Mesothelioma Interest Group (IMIG) have created a database that includes information on 3101 patients with mesothelioma from 15 centers diagnosed between 1995 and 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/21\">",
"     21",
"    </a>",
"    ]. The information in this database is being correlated with various prognostic factors, and hopefully will provide the basis for further revisions in the staging system.",
"   </p>",
"   <p>",
"    In this database, the mean patient age was 63 years and the male female ratio was 4:1. Histologic classification was epithelial in 62 percent, sarcomatoid in 8 percent, and biphasic in 16 percent of cases. Approximately one-half of cases had a history of asbestos exposure, and no data on asbestos exposure was available for another 31 percent of cases. The database provides insights into prognosis of malignant pleural mesothelioma and may eventually facilitate revisions in the staging system.",
"   </p>",
"   <p>",
"    Key findings in the initial report from this database include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1056 cases, both clinical and pathologic staging were available. Clinical staging was unreliable, with approximately 80 percent of clinical stage I patients and 70 percent of stage II patients being upstaged following pathologic evaluation based upon surgery (",
"      <a class=\"graphic graphic_figure graphicRef87269 \" href=\"mobipreview.htm?29/63/30718\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Based upon pathologic staging when available and clinical staging for those not undergoing pathologic staging (",
"      <a class=\"graphic graphic_table graphicRef81665 \" href=\"mobipreview.htm?43/19/44349\">",
"       table 1",
"      </a>",
"      ), patients with stage I, II, III, and IV disease had median survivals of 20, 19, 16, and 11 months, respectively (",
"      <a class=\"graphic graphic_figure graphicRef87270 \" href=\"mobipreview.htm?35/39/36479\">",
"       figure 2",
"      </a>",
"      ) . For patients who underwent surgery with curative intent, median survivals for stages I, II, III, and IV were 30, 22, 16, and 12 months, respectively.",
"     </li>",
"     <li>",
"      There was a clear relationship between histologic type of mesothelioma and survival when all patients undergoing surgery were considered. Median survivals for those with epithelial, biphasic, and sarcomatoid histology were 19, 13, and 8 months (",
"      <a class=\"graphic graphic_figure graphicRef87271 \" href=\"mobipreview.htm?16/15/16639\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16617048\">",
"    <span class=\"h3\">",
"     Prognostic scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostic scoring systems that incorporate both the extent of disease, as well as systemic factors, may provide useful information. The two most widely used scoring systems were developed by the Cancer and Leukemia Group B (CALGB) and the European Organisation for Research and Treatment of Cancer (EORTC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     CALGB index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CALGB evaluated the impact of clinical characteristics on the survival of 337 patients treated with chemotherapy for advanced disease in sequential phase II treatment studies over a ten-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/34\">",
"     34",
"    </a>",
"    ]. In multivariate analysis, pleural (as compared to peritoneal or pericardial) involvement, serum lactate dehydrogenase (LDH) greater than 500 int.",
"    <span class=\"nowrap\">",
"     unit/L,",
"    </span>",
"    poor performance status, chest pain, platelet count over",
"    <span class=\"nowrap\">",
"     400,000/microL,",
"    </span>",
"    nonepithelial histology, and age older than 75 years jointly predicted poor survival. Six distinct prognostic subgroups were generated with median survival times ranging from 1.4 to 13.9 months. The median survival overall was 7.0 months. This prognostic schema was subsequently validated in an American phase II trial evaluating the investigational agent ranpirnase (",
"    <a class=\"graphic graphic_table graphicRef74485 \" href=\"mobipreview.htm?16/10/16557\">",
"     table 2",
"    </a>",
"    ) and in an independent European data set [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h4\">",
"     EORTC index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similarly, the EORTC reviewed data from 204 adults who were entered into five consecutive phase II trials over nine years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/37\">",
"     37",
"    </a>",
"    ]. When five factors were taken into consideration (poor performance status, high WBC count, male gender, sarcomatous subtype, and the certainty of the diagnosis), a good and bad prognostic group could be discerned, with one year survival rates of 40 and 12 percent, respectively. Median survival from the date of study entry was 8.4 months.",
"   </p>",
"   <p>",
"    The relevance of these earlier prognostic indicators is somewhat limited given that the study was performed in the pre-pemetrexed era. However, the prognostic significance of the EORTC index has subsequently been confirmed in a multivariate analysis of a phase III trial assessing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21525?source=see_link\">",
"     raltitrexed",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32552/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link&amp;anchor=H1937733690#H1937733690\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\", section on 'Raltitrexed plus cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesothelioma causes its morbidity and mortality primarily by local invasion. Patients typically develop shortness of breath and chest pain as the tumor gradually obliterates the pleural space and replaces any pleural fluid. As the tumor spreads, deoxygenated blood is shunted through the encased lung, leading to fatigue, dyspnea, and hypoxemia that is often refractory to supplemental oxygen. Local invasion of crucial thoracic structures can result in symptoms such as dysphagia, hoarseness, spinal cord compression, brachial plexopathy, Horner&rsquo;s syndrome, or superior vena cava syndrome.",
"   </p>",
"   <p>",
"    Metastases may occur to the opposite lung, brain, and other extrathoracic sites. Extension of the malignancy through the diaphragm into the abdominal cavity may occur, particularly in patients who have prolonged survival after primary aggressive therapy of their thoracic disease. Spread throughout the abdomen in a manner similar to primary peritoneal mesothelioma may be observed. In such patients, invasion of liver and other organs is rare, but bowel obstruction can be a major problem.",
"   </p>",
"   <p>",
"    The majority of affected patients die from local extension and respiratory failure; tumor extension below the diaphragm may result in death from small bowel obstruction. Patients may also die from arrhythmias, heart failure, or stroke caused by tumor invasion of the heart or pericardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/15/33010?source=see_link\">",
"       \"Patient information: Pleural mesothelioma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/17/3347?source=see_link\">",
"       \"Patient information: Asbestos exposure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with malignant pleural mesothelioma typically present with pulmonary symptoms. Chest imaging typically shows unilateral pleural thickening and pleural effusion. Paraneoplastic syndromes can be associated with pleural mesothelioma, but rarely are the initial manifestation of disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of malignant mesothelioma requires a tissue sample. The differential diagnosis of malignant pleural mesothelioma includes inflammatory reactions, which can mimic pleural mesothelioma, as well as metastases from other malignancies. Thoracentesis and closed pleural biopsy are the initial procedures in most cases. If this is not diagnostic, surgical intervention is required to obtain an adequate tissue sample. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tissue diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical staging primarily relies upon imaging studies to assess the extent of disease and determine whether or not the patient is a candidate for surgical resection. However, clinical staging often underestimates the extent of disease, and intraoperative staging provides a more reliable assessment of whether or not the patient is a candidate for surgical resection. (See",
"      <a class=\"local\" href=\"#H16615464\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with malignant pleural mesothelioma is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=see_link\">",
"       \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=see_link\">",
"       \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pass HI, Vogelzang NJ, Hahn SM, Carbone M. Benign and malignant mesothelioma. In: Cancer: Principles &amp; Practice of Oncology, 9th, DeVita VT, Lawrence TS, Rosenberg SA.  (Eds), LWW, 2011. p.2052.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/2\">",
"      B&eacute;nard F, Sterman D, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/3\">",
"      Yildirim H, Metintas M, Entok E, et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol 2009; 4:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/4\">",
"      Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/5\">",
"      Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992; 16:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/6\">",
"      Ord&oacute;&ntilde;ez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/7\">",
"      Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/8\">",
"      Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/9\">",
"      Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/10\">",
"      Davies HE, Sadler RS, Bielsa S, et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009; 180:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/11\">",
"      Lee YC. Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer? Thorax 2007; 62:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/12\">",
"      Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/13\">",
"      Hiraki A, Aoe K, Ueoka H. Asbestos exposure and serum osteopontin. N Engl J Med 2006; 354:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/14\">",
"      Mu&ntilde;oz A, Barcel&oacute; R, L&oacute;pez-Vivanco G. Malignant mesothelioma. N Engl J Med 2006; 354:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/15\">",
"      Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/16\">",
"      Socola F, Loaiza-Bonilla A, Bustinza-Linares E, et al. Recurrent thrombotic thrombocytopenic purpura-like syndrome as a paraneoplastic phenomenon in malignant peritoneal mesothelioma: a case report and review of the literature. Case Rep Oncol Med 2012; 2012:619348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/17\">",
"      Wong SF, Newland L, John T, White SC. Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report. J Med Case Rep 2012; 6:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/18\">",
"      Li JY, Yong TY, Kuss BJ, et al. Malignant pleural mesothelioma with associated minimal change disease and acute renal failure. Ren Fail 2010; 32:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/19\">",
"      Bech C, S&oslash;rensen JB. Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome. J Thorac Oncol 2008; 3:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/20\">",
"      Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 1993; 72:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/21\">",
"      Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 2012; 7:1631.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer. Pleural mesothelioma. In: Cancer Staging Manual, Seventh Edition, Springer, 2010. p.271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/23\">",
"      Richards WG. Recent advances in mesothelioma staging. Semin Thorac Cardiovasc Surg 2009; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/24\">",
"      Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 1992; 159:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/25\">",
"      Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999; 172:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/26\">",
"      Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imaging in malignant pleural mesothelioma. Semin Oncol 2002; 29:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/27\">",
"      Miller WT Jr, Gefter WB, Miller WT Sr. Asbestos-related chest diseases: plain radiographic findings. Semin Roentgenol 1992; 27:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/28\">",
"      Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003; 126:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/29\">",
"      S&oslash;rensen JB, Ravn J, Loft A, et al. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg 2008; 34:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/30\">",
"      Plathow C, Staab A, Schmaehl A, et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol 2008; 43:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/31\">",
"      Wilcox BE, Subramaniam RM, Peller PJ, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009; 10:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/32\">",
"      Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 2005; 80:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/33\">",
"      Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest 1995; 107:345S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/34\">",
"      Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/35\">",
"      Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/36\">",
"      Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002; 20:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/37\">",
"      Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32552/abstract/38\">",
"      Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007; 25:5770.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4627 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32552=[""].join("\n");
var outline_f31_50_32552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16617531\">",
"      Clinical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16617524\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1568139496\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1568139503\">",
"      - Fibulin-3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1568139510\">",
"      - Mesothelin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1568139517\">",
"      - Osteopontin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H539890722\">",
"      Paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tissue diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16615464\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16615788\">",
"      Staging systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16615949\">",
"      Staging evaluaton",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16616892\">",
"      - Chest CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16616570\">",
"      - MR imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16616577\">",
"      - PET and integrated PET-CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16616377\">",
"      - Surgical staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16615795\">",
"      Stage and prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16617040\">",
"      - IASLC IMIG database",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16617048\">",
"      - Prognostic scoring systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CALGB index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EORTC index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4627\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4627|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/52/20288\" title=\"diagnostic image 1A\">",
"      Malignant mesothelioma I CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/31/2545\" title=\"diagnostic image 1B\">",
"      Malignant mesothelioma II CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/8/41088\" title=\"diagnostic image 2A\">",
"      Mesothelioma MRI I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/27/40383\" title=\"diagnostic image 2B\">",
"      Mesothelioma MRI II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4627|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/63/30718\" title=\"figure 1\">",
"      Differences between clinical and pathological staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/39/36479\" title=\"figure 2\">",
"      Survival for all patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/15/16639\" title=\"figure 3\">",
"      Relationship between histological subtype and survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4627|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/19/44349\" title=\"table 1\">",
"      TNM stage mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/10/16557\" title=\"table 2\">",
"      Mesothelioma prognostic groups",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7622?source=related_link\">",
"      Epidemiology of malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17754?source=related_link\">",
"      Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29204?source=related_link\">",
"      Pathology of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/17/3347?source=related_link\">",
"      Patient information: Asbestos exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/15/33010?source=related_link\">",
"      Patient information: Pleural mesothelioma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/21/42329?source=related_link\">",
"      Systemic treatment for unresectable malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_50_32553="Haloperidol: Drug information";
var content_f31_50_32553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Haloperidol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/63/37877?source=see_link\">",
"    see \"Haloperidol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/51/38711?source=see_link\">",
"    see \"Haloperidol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6697563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Haldol&reg;;",
"     </li>",
"     <li>",
"      Haldol&reg; Decanoate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Haloperidol LA&reg;;",
"     </li>",
"     <li>",
"      Apo-Haloperidol&reg;;",
"     </li>",
"     <li>",
"      Haloperidol Injection, USP;",
"     </li>",
"     <li>",
"      Haloperidol Long Acting;",
"     </li>",
"     <li>",
"      Haloperidol-LA;",
"     </li>",
"     <li>",
"      Haloperidol-LA Omega;",
"     </li>",
"     <li>",
"      Novo-Peridol;",
"     </li>",
"     <li>",
"      PMS-Haloperidol;",
"     </li>",
"     <li>",
"      PMS-Haloperidol LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F178603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Typical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F178557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psychosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 0.5-5 mg 2-3 times/day; usual maximum: 30 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (as lactate): 2-5 mg every 4-8 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (as decanoate): Initial: 10-20 times the daily oral dose administered at 4-week intervals. Maintenance dose: 10-15 times initial oral dose; used to stabilize psychiatric symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Delirium in the intensive care unit, treatment (unlabeled use, unlabeled route):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The optimal dose and regimen of haloperidol for the treatment of severe agitation and/or delirium has not been established. Currently, there are no studies evaluating the role of haloperidol on duration or severity of delirium. Haloperidol has been used for symptomatic treatment (severe agitation) of delirious patients. Current guidelines do not advocate use of haloperidol for the treatment or prevention of delirium due to insufficient evidence (Barr, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 0.5-10 mg depending on degree of agitation; if inadequate response, may repeat bolus dose (with sequential doubling of initial bolus dose) every 15-30 minutes until calm achieved, then administer 25% of the last bolus dose every 6 hours; monitor ECG and QT",
"     <sub>",
"      c",
"     </sub>",
"     interval. After the patient is controlled, haloperidol therapy should be tapered over several days. This strategy is based upon expert opinion; efficacy and safety have not been formally evaluated (Tesar, 1988).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation may occur with cumulative doses &ge;35 mg per day and the risk of torsade de pointes is greater if &ge;35 mg is received within &lt;6 hours (Sharma, 1998). Continuous infusions have also been used with doses in the range of 0.5-2 mg/hour with an optional loading dose of 2.5 mg (Reade, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Delirium in the intensive care unit (patients at high risk of delirium), prevention (unlabeled use, unlabeled route):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The optimal dose and regimen of haloperidol for prevention of ICU delirium has not been established. Current guidelines do not advocate use of haloperidol for the treatment or prevention of delirium due to insufficient evidence (Barr, 2013). Haloperidol may decrease the incidence of delirium (Van den Boogaard, 2012; Wang, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.5 mg followed by a continuous infusion of 0.1 mg/hour for 12 hours (Wang, 2012)",
"     <b>",
"      or",
"     </b>",
"     0.5-1 mg every 8 hours (Van den Boogaard, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rapid tranquilization of severely-agitated patient (unlabeled use; administer every 30-60 minutes):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 5-10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (as lactate): 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Average total dose (oral or I.M.) for tranquilization: 10-20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postoperative nausea and vomiting (PONV) (unlabeled use):",
"     </b>",
"     I.M., I.V.: 0.5-2 mg (Gan, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F178580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/51/38711?source=see_link\">",
"      see \"Haloperidol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation/psychotic disorders:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 3-12 years (15-40 kg):",
"     </i>",
"     Initial: 0.5 mg/day given in 2-3 divided doses; increase by 0.5 mg every 5-7 days; maximum: 0.15 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Usual maintenance:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nonpsychotic disorders, Tourette&rsquo;s disorder: 0.05-0.075 mg/kg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Psychotic disorders: 0.05-0.15 mg/kg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 6-12 years:",
"     </i>",
"     Sedation/psychotic disorders: I.M. (as lactate): 1-3 mg/dose every 4-8 hours to a maximum of 0.15 mg/kg/day; convert to oral therapy as soon as able.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F178558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nonpsychotic patient, dementia behavior (unlabeled use): Initial: Oral: 0.25-0.5 mg 1-2 times/day; increase dose at 4- to 7-day intervals by 0.25-0.5 mg/day. Increase dosing intervals (twice daily, 3 times/day, etc) as necessary to control response or side effects.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F178559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis/peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as decanoate [strength expressed as base]: 50 mg/mL (1 mL, 5 mL); 100 mg/mL (1 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Haldol&reg; Decanoate: 50 mg/mL (1 mL); 100 mg/mL (1 mL) [contains benzyl alcohol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as lactate [strength expressed as base]: 5 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Haldol&reg;: 5 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as lactate [strength expressed as base, concentrate]: 2 mg/mL (5 mL, 15 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F178529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection oil (decanoate): The decanoate injectable formulation should be administered I.M. only,",
"     <b>",
"      do not administer decanoate I.V.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection solution (lactate): The lactate injectable formulation may be administered I.V. (unlabeled route) or I.M.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution (lactate): Dilute the oral concentrate with water or juice before administration. Avoid skin contact with oral solution; may cause contact dermatitis.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F178610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amsacrine, bivalirudin, cimetidine, cisatracurium, cladribine, dexmedetomidine, dobutamine, docetaxel, dopamine, doxorubicin liposome, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fludarabine, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, lidocaine, linezolid, lorazepam, melphalan, methadone, nitroglycerin, norepinephrine, ondansetron, oxaliplatin, paclitaxel, pemetrexed, phenylephrine, propofol, quinupristin/dalfopristin, remifentanil, sufentanil, tacrolimus, teniposide, theophylline, thiotepa, tigecycline, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, dexamethasone sodium phosphate, fluconazole, foscarnet, furosemide, gallium nitrate, heparin, ketorolac, piperacillin/tazobactam, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aztreonam, metoclopramide, midazolam, morphine, nitroprusside.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Buprenorphine with glycopyrrolate, lorazepam, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diphenhydramine, heparin, hydroxyzine, ketorolac, morphine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Benztropine, hydromorphone, scopolamine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F178528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of schizophrenia; control of tics and vocal utterances of Tourette's disorder in children and adults; severe behavioral problems in children",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F178600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nonschizophrenia psychosis; may be used for the emergency sedation of severely-agitated or delirious patients; treatment of ICU delirium; adjunctive treatment of ethanol dependence; postoperative nausea and vomiting (alternative therapy); psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F178612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Haldol&reg; may be confused with Halcion&reg;, Halog&reg;, Stadol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Haldol [U.S. and multiple international markets] may be confused with Halotestin brand name for fluoxymesterone [Great Britain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F178601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Abnormal T waves with prolonged ventricular repolarization, arrhythmia, hyper-/hypotension, QT prolongation, sudden death, tachycardia, torsade de pointes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, akathisia, altered central temperature regulation, anxiety, confusion, depression, drowsiness, dystonic reactions, euphoria, extrapyramidal reactions, headache, insomnia, lethargy, neuroleptic malignant syndrome (NMS), pseudoparkinsonian signs and symptoms, restlessness, seizure, tardive dyskinesia, tardive dystonia, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, contact dermatitis, hyperpigmentation, photosensitivity (rare), pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast engorgement, galactorrhea, gynecomastia, hyper-/hypoglycemia, hyponatremia, lactation, mastalgia, menstrual irregularities, sexual dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dyspepsia, hypersalivation, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Priapism, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis (rare), leukopenia, leukocytosis, neutropenia, anemia, lymphomonocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, obstructive jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, laryngospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, heat stroke",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F178532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to haloperidol or any component of the formulation; Parkinson's disease; severe CNS depression; coma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F178513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction and prolong QT interval; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics, but risk may be increased with doses exceeding recommendations and/or intravenous administration (unlabeled route). Use with caution or avoid use in patients with electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), hypothyroidism, familial long QT syndrome, concomitant medications which may augment QT prolongation, or any underlying cardiac abnormality which may also potentiate risk. Monitor ECG closely for dose-related QT effects. Adverse effects of decanoate may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, haloperidol has a low potency of cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of dystonia (and possibly other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: May increase prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pigmentary retinopathy: Antipsychotics have  been associated with pigmentary retinopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Haloperidol is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use is contraindicated in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Avoid in thyrotoxicosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria). Increased risk for developing tardive dyskinesia, particularly elderly women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some tablets contain tartrazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral administration: Hypotension may occur, particularly with parenteral administration. Risk of QT prolongation, torsade de pointes, and sudden death appear to be increased with intravenous administration, particularly at higher doses. Although the short-acting form (lactate) is used clinically intravenously, the I.V. use of the injection is not an FDA-approved route of administration; the decanoate form should never be administered intravenously.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F178598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Haloperidol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ChlorproMAZINE: May enhance the QTc-prolonging effect of Haloperidol. ChlorproMAZINE may increase the serum concentration of Haloperidol. Haloperidol may increase the serum concentration of ChlorproMAZINE. Management: Consider alternatives to combined treatment with these agents. If combined treatment cannot be avoided, monitor for signs and symptoms of prolonged QTc interval (e.g. arrhythmias).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: May enhance the QTc-prolonging effect of Haloperidol. FLUoxetine may increase the serum concentration of Haloperidol. Management: Consider alternatives to this combination when available.  If the combination is used, monitor for evidence of QTc prolongation and increased systemic haloperidol concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Haloperidol. Management: Monitor for increased haloperidol concentrations/effects when patients are receiving fluvoxamine, particularly when fluvoxamine dose is 150 mg/day or greater.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May decrease the serum concentration of Haloperidol. Management: Monitor patients closely for signs/symptoms of reduced clinical response to haloperidol if concurrent use with glycopyrrolate is required.  When possible, consider avoiding concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Haloperidol may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Haloperidol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F178548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10869024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies. Haloperidol crosses the placenta. There are case reports of limb malformations following first trimester exposure in humans. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F178566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F178535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Haloperidol is found in breast milk and has been detected in the plasma and urine of nursing infants. Developmental decline was observed in 3 nursing infants following maternal use of haloperidol in combination with chlorpromazine. Breast engorgement, gynecomastia, and lactation are known side effects with the use of haloperidol.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F178534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Haloperidol Lactate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (120 mL): $54.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Haldol Decanoate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $75.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (1 mL): $143.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Haldol Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (1 mL): $17.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Haloperidol Decanoate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (1 mL): $25.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (5 mL): $75.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Haloperidol Lactate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (1 mL): $1.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Haloperidol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $24.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $36.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $50.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $81.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $143.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $275.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F178522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; lipid profile, fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS); ECG (with off-label intravenous administration)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <i>",
"      ICU delirium:",
"     </i>",
"     Monitor either the Confusion Assessment Method for the ICU (CAM-ICU) or the Intensive Care Delirium Screening Checklist (ICDSC)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F178525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 5-20 ng/mL (SI: 10-40 nmol/L) (psychotic disorders - less for Tourette's and mania)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;42 ng/mL (SI: &gt;84 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F178536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aloperidin (GR);",
"     </li>",
"     <li>",
"      Decadol (PL);",
"     </li>",
"     <li>",
"      Haldol (AT, BE, BZ, DE, EC, GB, HR, IE, LU, MX, NI, NO, NZ, PA, PE, PK, PT, SE, VE);",
"     </li>",
"     <li>",
"      Haldol Decanoas (AE, BB, BF, BG, BH, BJ, BM, BS, CH, CI, CR, CY, CZ, DO, EG, ET, FR, GH, GM, GN, GT, GY, HK, HN, ID, IL, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, PY, QA, SA, SC, SD, SL, SN, SR, SV, SY, TN, TT, TW, TZ, UG, UY, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Haldol decanoas (LU);",
"     </li>",
"     <li>",
"      Haldol Decanoate (AU);",
"     </li>",
"     <li>",
"      Haldol Decanoato (BR, CN);",
"     </li>",
"     <li>",
"      Haldol depo (HR);",
"     </li>",
"     <li>",
"      Haloper (DE, RU);",
"     </li>",
"     <li>",
"      Haloperidol Decanoat (HU);",
"     </li>",
"     <li>",
"      Haloperidol Esteve (ES);",
"     </li>",
"     <li>",
"      Haloperidol Prodes (ES);",
"     </li>",
"     <li>",
"      Haloperidol-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Haloperil (MX);",
"     </li>",
"     <li>",
"      Halopidol decanoato (AR, CO);",
"     </li>",
"     <li>",
"      Haloxen (SG);",
"     </li>",
"     <li>",
"      Haridol Decanoate (TH);",
"     </li>",
"     <li>",
"      Haridol-D (CL);",
"     </li>",
"     <li>",
"      Manace (MY);",
"     </li>",
"     <li>",
"      Mapress (MY);",
"     </li>",
"     <li>",
"      Motivan (SG);",
"     </li>",
"     <li>",
"      Norodol (TR);",
"     </li>",
"     <li>",
"      Pericate (IL);",
"     </li>",
"     <li>",
"      Senorm L.A. (IN);",
"     </li>",
"     <li>",
"      Seranace (GB, IE, ZA);",
"     </li>",
"     <li>",
"      Seredol Deca (PH);",
"     </li>",
"     <li>",
"      Serenace (BD, CL, GB, JP, SG);",
"     </li>",
"     <li>",
"      Serenase (FI);",
"     </li>",
"     <li>",
"      Serenase Dekanoat (DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F178512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Haloperidol is a butyrophenone antipsychotic which blocks postsynaptic mesolimbic dopaminergic D",
"     <sub>",
"      1",
"     </sub>",
"     and D",
"     <sub>",
"      2",
"     </sub>",
"     receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F178531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Sedation: I.M., I.V.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Decanoate: 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8-18 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic: 50% to 60% glucuronidation (inactive); 23% CYP3A4-mediated reduction to inactive metabolites (some back-oxidation to haloperidol); and 20% to 30% CYP3A4-mediated N-dealkylation, including minor oxidation pathway to toxic pyridinium derivative (Kudo, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 18 hours; Decanoate: 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 2-6 hours; I.M.: 20 minutes; Decanoate: 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (30%, 1% as unchanged drug); feces (15%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aunsholt NA, &ldquo;Prolonged QT Interval and Hypokalemia Caused by Haloperidol,&rdquo;",
"      <i>",
"       Acta Psychiatr Scand",
"      </i>",
"      , 1989, 79(4):411-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/2735214/pubmed\" id=\"2735214\" target=\"_blank\">",
"        2735214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barton MD, Libonati M, and Cohen PJ, &ldquo;The Use of Haloperidol for Treatment of Postoperative Nausea and Vomiting &minus; A Double-Blind Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1975, 42(4):508-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/1091183/pubmed\" id=\"1091183\" target=\"_blank\">",
"        1091183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bauer M, &ldquo;Concurrent Agranulocytosis and Acute Hepatitis Resulting From Combination of Classic Neuroleptics and Subsequent Successful Clozapine Treatment,&rdquo;",
"      <i>",
"       Pharmacopsychiatry",
"      </i>",
"      , 1995, 28(1):29-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7746843/pubmed\" id=\"7746843\" target=\"_blank\">",
"        7746843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cole RM, Robinson F, Harvey L, et al, &ldquo;Successful Control of Intractable Nausea and Vomiting Requiring Combined Ondansetron and Haloperidol in a Patient With Advanced Cancer,&rdquo;",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 1994, 9(1):48-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7513334/pubmed\" id=\"7513334\" target=\"_blank\">",
"        7513334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Di Salvo TG and O'Gara PT, &ldquo;Torsade de Pointes Caused by High-Dose Intravenous Haloperidol in Cardiac Patients,&rdquo;",
"      <i>",
"       Clin Cardiol",
"      </i>",
"      , 1995, 18(5):285-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7628136/pubmed\" id=\"7628136\" target=\"_blank\">",
"        7628136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doenecke AL and Heuermann RC, &ldquo;Treatment of Haloperidol Abuse With Diphenhydramine,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1980, 137(4):487-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7361941/pubmed\" id=\"7361941\" target=\"_blank\">",
"        7361941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher H, &ldquo;A New Approach to Emergency Department Therapy of Migraine Headache With Intravenous Haloperidol: A Case Series,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1995, 13(1):119-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7782618/pubmed\" id=\"7782618\" target=\"_blank\">",
"        7782618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, &ldquo;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harada H, Igarashi M, Sugae S, et al, &ldquo;A Schizophrenic Patient Who Developed Extreme Hypothermia After an Increase in the Dose of Haloperidol: A Case Report,&rdquo;",
"      <i>",
"       Jpn J Psychiatry Neurol",
"      </i>",
"      , 1994, 48(3):595-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7891424/pubmed\" id=\"7891424\" target=\"_blank\">",
"        7891424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kubota T, Ishikura T, and Jibiki I, &ldquo;Alopecia Areata Associated With Haloperidol,&rdquo;",
"      <i>",
"       Jpn J Psychiatry Neurol",
"      </i>",
"      , 1994, 48(3):579-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7891421/pubmed\" id=\"7891421\" target=\"_blank\">",
"        7891421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kudo S and Ishizaki T, \"Pharmacokinetics of Haloperidol: An Update,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1999, 73(6):435-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahutte CK, Nakasato SK, and Light RW, &ldquo;Haloperidol and Sudden Death Due to Pulmonary Edema,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1982, 142(10):1951-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7125780/pubmed\" id=\"7125780\" target=\"_blank\">",
"        7125780",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Medlin R, Ransom M, and Kline J, &ldquo;Ethanol Potentiates Electromechanical Depression Induced by Haloperidol,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):499.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Clinical Guideline Centre, &ldquo;Delirium: Diagnosis, Prevention and Management,&rdquo; National Clinical Practice Guideline Number 103, 2010. Available at  file://www.nice.org.uk/CG103",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neidhart JA, Gagen MM, Wilson HE, et al, &ldquo;Comparative Trial of the Antiemetic Effects of THC and Haloperidol,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1981, 21(8-9 Suppl):38-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newport DJ, Calamaras MR, DeVane CL, et al, &ldquo;Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(8):1214-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/17671284/pubmed\" id=\"17671284\" target=\"_blank\">",
"        17671284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peabody CA, Warner MD, Whiteford HA, et al, &ldquo;Neuroleptics and the Elderly,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1987, 35(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/2880887/pubmed\" id=\"2880887\" target=\"_blank\">",
"        2880887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plotkin DA, Plotkin D, and Okun R, &ldquo;Haloperidol in the Treatment of Nausea and Vomiting Due to Cytotoxic Drug Administration,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      ,1973, 15(9):599-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/4201543/pubmed\" id=\"4201543\" target=\"_blank\">",
"        4201543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reade MC, O&rsquo;Sullivan K, Bates S, et al, &ldquo;Dexmedetomidine vs Haloperidol in Delirious, Agitate, Intubated Patients: A Randomized Open-Label Trial,&rdquo;",
"      <i>",
"       Crit Care",
"      </i>",
"      , 2009, 13(3):R75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/19454032/pubmed\" id=\"19454032\" target=\"_blank\">",
"        19454032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riker RR, Fraser GL, and Cox PM, &ldquo;Continuous Infusion of Haloperidol Controls Agitation in Critically Ill Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1994, 22(3):433-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/8124994/pubmed\" id=\"8124994\" target=\"_blank\">",
"        8124994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Risse SC and Barnes R, &ldquo;Pharmacologic Treatment of Agitation Associated With Dementia,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(5):368-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/2870097/pubmed\" id=\"2870097\" target=\"_blank\">",
"        2870097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saltz BL, Woerner MG, Kane JM, et al, &ldquo;Prospective Study of Tardive Dyskinesia Incidence in the Elderly,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 266(17):2402-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/1681122/pubmed\" id=\"1681122\" target=\"_blank\">",
"        1681122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz M, Weller B, Erdreich M, et al, &ldquo;Rabbit Syndrome and Tardive Dyskinesia: Two Complications of Chronic Neuroleptic Treatment,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(5):212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/7737962/pubmed\" id=\"7737962\" target=\"_blank\">",
"        7737962",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert RD, &ldquo;Therapeutic Drug Monitoring: Psychotropic Drugs,&rdquo;",
"      <i>",
"       J Pharm Pract",
"      </i>",
"      , 1984, 6:403-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Serrano AC, &ldquo;Haloperidol - Its Use in Children,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1981, 42(4):154-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/6937455/pubmed\" id=\"6937455\" target=\"_blank\">",
"        6937455",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma ND, Rosman HS, Padhi ID, et al, &ldquo;Torsades de Pointes Associated With Intravenous Haloperidol in Critically Ill Patients,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1998, 81(2):238-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/9591913/pubmed\" id=\"9591913\" target=\"_blank\">",
"        9591913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silvey L, Carpenter JT Jr, Wheeler RH, et al, &ldquo;A Randomized Comparison of Haloperidol Plus Dexamethasone Versus Prochlorperazine Plus Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1988, 6(9):1397-400.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/3047334/pubmed\" id=\"3047334\" target=\"_blank\">",
"        3047334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spencer EK, Kafantaris V, Padron-Gayol MV, et al, &ldquo;Haloperidol in Schizophrenic Children: Early Findings From a Study in Progress,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 1992, 28(2):183-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/1513922/pubmed\" id=\"1513922\" target=\"_blank\">",
"        1513922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tesar GE and Stern TA, &ldquo;Analytic Reviews: Rapid Tranquilization of the Agitated Intensive Care Unit Patient,&rdquo;",
"      <i>",
"       J Intensive Care Med",
"      </i>",
"      , 1988, 3(4):195-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whalley LJ, Blain PG, and Prime JK, &ldquo;Haloperidol Secreted in Breast Milk,&rdquo;",
"      <i>",
"       Br Med J (Clin Res Ed)",
"      </i>",
"      , 1981, 282(6278):1746-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/6786603/pubmed\" id=\"6786603\" target=\"_blank\">",
"        6786603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilt JL, Minnema AM, Johnson RF, et al, &ldquo;Torsade de Pointes Associated With the Use of Intravenous Haloperidol,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1993, 119(5):391-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/8338292/pubmed\" id=\"8338292\" target=\"_blank\">",
"        8338292",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshida K, Smith B, and Kumar R, &ldquo;Psychotropic Drugs in Mothers' Milk: A Comprehensive Review of Assay Methods, Pharmacokinetics and of Safety of Breast-Feeding,&rdquo;",
"      <i>",
"       J Psychopharmacol",
"      </i>",
"      , 1999, 13(1):64-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/10221361/pubmed\" id=\"10221361\" target=\"_blank\">",
"        10221361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshida K, Smith B, Craggs M, et al, &ldquo;Neuroleptic Drugs in Breast-Milk: A Study of Pharmacokinetics and of Possible Adverse Effects in Breast-Fed Infants,&rdquo;",
"      <i>",
"       Psychol Med",
"      </i>",
"      , 1998, 28(1):81-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/50/32553/abstract-text/9483685/pubmed\" id=\"9483685\" target=\"_blank\">",
"        9483685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8516 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32553=[""].join("\n");
var outline_f31_50_32553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6697563\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178552\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178553\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178603\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178557\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178580\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178558\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178559\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897441\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178524\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178509\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178529\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178610\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178528\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178600\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178612\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178601\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178532\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178513\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178598\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178518\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178548\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178520\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10869024\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178566\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178535\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178534\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178522\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178525\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178536\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178512\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178531\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/63/37877?source=related_link\">",
"      Haloperidol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/51/38711?source=related_link\">",
"      Haloperidol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_50_32554="Restless legs syndrome";
var content_f31_50_32554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Restless legs syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/50/32554/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/50/32554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restless legs syndrome (RLS) refers to symptoms of spontaneous, continuous leg movements associated with unpleasant paresthesias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/1\">",
"     1",
"    </a>",
"    ]. There is an urge to move the legs, the symptoms worsen at rest and at night, and are relieved by movement. Sleep disturbance and a frequent association with involuntary, jerking movements of the legs during sleep, known as periodic leg movements of sleep (PLMS), are common. Nocturnal leg cramps are a separate disorder and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=see_link\">",
"     \"Nocturnal leg cramps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild symptoms of RLS occur in 5 to 15 percent of the population; prevalence figures vary widely depending upon the population surveyed and severity of symptoms required for inclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a population study of RLS that used standard diagnostic criteria, 15,391 subjects (&ge;18-years-old) from the United States and five European countries (France, Germany, Italy, Spain, and the United Kingdom) completed questionnaires and the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RLS symptoms of any frequency were reported by 7.2 percent.",
"     </li>",
"     <li>",
"      RLS symptoms occurred at least twice a week and were reported as moderately or severely distressing by 2.7 percent.",
"     </li>",
"     <li>",
"      The prevalence of RLS was approximately twice as high for women compared with men.",
"     </li>",
"     <li>",
"      The prevalence of RLS increased with age up to age 79, and then declined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A previous survey also found that the prevalence of restless legs (with symptoms experienced on five or more nights per month) increased with age, from 3 percent of participants ages 18 to 29, compared with 10 percent of those ages 30 to 79 and 19 percent of those ages 80 or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/7\">",
"     7",
"    </a>",
"    ]. Increasing parity may be associated with an increased risk of RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RLS also occurs in children. A large population-based internet survey study from the United Kingdom and United States found that the prevalence of definite RLS in children 8 to 17 years old was approximately 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/9\">",
"     9",
"    </a>",
"    ]. The presence of moderately severe or distressing RLS symptoms occurring two or more times a week was found in 0.5 percent of children ages 8 to 11 years and 1.0 percent of those 12 to 17 years old. A biologic parent with RLS symptoms was noted for &gt;70 percent of children with RLS.",
"   </p>",
"   <p>",
"    In a telephone survey of patients with RLS, 25 percent experienced their first symptoms between ages 11 and 20 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/10\">",
"     10",
"    </a>",
"    ]. Misdiagnoses such as \"growing pains\" and attention deficit hyperactivity disorder were common, and medical attention was often not sought until after age 40 when symptoms frequently begin to progress. In a retrospective study, 32 of 538 children and adolescent subjects (5.9 percent) presenting to a sleep disorders clinic had restless legs syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/11\">",
"     11",
"    </a>",
"    ]. Low serum ferritin (&lt;50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [&lt;50",
"    <span class=\"nowrap\">",
"     mcg/L])",
"    </span>",
"    was found in 20 of 24 subjects (83 percent) who had ferritin levels determined.",
"   </p>",
"   <p>",
"    A number of retrospective studies suggest that children and adults with RLS have a relatively high rate of comorbid psychiatric disorders, such as attention deficit hyperactivity disorder and mood disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. However, the implications of these data are unclear, since psychotropic medications may induce symptoms similar to RLS or exacerbate pre-existing RLS, and conversely, RLS symptoms may mimic those in psychiatric disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases RLS is a primary idiopathic disorder, but it also can be associated with a variety of underlying medical disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary RLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of primary (or idiopathic) RLS is unknown. However, a family history consistent with autosomal dominant inheritance is present in more than 40 percent of patients with idiopathic RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This observation, in combination with reports of several large kindreds with RLS, suggests a genetic basis for the disorder. A genetic component is further supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a twin study, 10 of 12 monozygotic twin pairs were concordant for RLS, although there was considerable variance in age of onset and symptom severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic linkage studies have identified potential susceptibility loci for RLS on chromosomes 2q [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/19\">",
"       19",
"      </a>",
"      ], 9p [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], 12q [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/22,23\">",
"       22,23",
"      </a>",
"      ], 14q [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/24\">",
"       24",
"      </a>",
"      ], and 20p [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a genome-wide association study (GWAS) of 401 subjects with RLS and 1644 controls, all of European descent, RLS was associated with three genetic loci: MEIS1 on chromosome 2p, BTBD9 on chromosome 6p, and a third locus between MAP2K5 and LBXCOR1 on chromosome 15q [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/26\">",
"       26",
"      </a>",
"      ]. A fourth locus, PTPRD on chromosome 9p23-24, was identified in another GWAS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/27\">",
"       27",
"      </a>",
"      ], and an association of RLS with the PTPRD variant rs1975197 was confirmed in a family-based and population-based genetic study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/28\">",
"       28",
"      </a>",
"      ]. An association with BTBD9 was also found by a GWAS from Iceland in a subset of 306 subjects with RLS who had periodic limb movements of sleep [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Periodic limb movements of sleep'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There is a high incidence of RLS in spinocerebellar ataxia type 3 (Machado-Joseph disease) that is unrelated to the incidence of peripheral neuropathy in that disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several neurophysiologic changes have been identified in patients with RLS, including reduced motor cortex inhibition, spinal flexor reflex hyperactivity, and brainstem reflex abnormalities, but these are nonspecific findings, the significance of which is currently undetermined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of brain dopamine metabolism suggest a central nervous system cause for RLS. One hypothesis holds that RLS arises from dysfunction of hypothalamic dopaminergic cells that are the source of spinal cord dopamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/32\">",
"     32",
"    </a>",
"    ]. Data from functional imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) are conflicting, having demonstrated reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/35\">",
"     35",
"    </a>",
"    ], or unchanged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/36\">",
"     36",
"    </a>",
"    ] basal ganglia dopamine receptor binding and 18F-Dopa uptake in patients with RLS compared with control subjects. This is of particular interest since there is probably an increased incidence of RLS in Parkinson disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain iron metabolism may also play a role. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Iron deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypocretins are hypothalamic neuropeptide transmitters that participate in the normal control of the sleep wake cycle and are depleted in the pathophysiology of narcolepsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=see_link&amp;anchor=H3830881#H3830881\">",
"     \"Clinical features and diagnosis of narcolepsy\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypocretins increase arousal and interact with the dopamine system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/38\">",
"     38",
"    </a>",
"    ]. A small clinical study also found that increases in hypocretin levels in the cerebrospinal fluid were associated with an increased incidence of restless legs syndrome, particularly early onset disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secondary RLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;RLS can occur secondary to a number of disorders including iron deficiency, uremia, diabetes mellitus, rheumatic disease, and venous insufficiency, among others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency has been considered a possible cause of RLS since the original publications on this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/40\">",
"     40",
"    </a>",
"    ]. Subsequently, the relationship between iron status and RLS has been examined in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 18 elderly patients with RLS and 18 matched controls, the serum ferritin concentration was significantly lower in patients with RLS (33 versus 59",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [33 versus 59",
"      <span class=\"nowrap\">",
"       mcg/L])",
"      </span>",
"      and was inversely correlated with the severity of symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/41\">",
"       41",
"      </a>",
"      ]. Although the hemoglobin concentration in patients and controls was similar, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"       ferrous sulfate",
"      </a>",
"      for two months reduced RLS symptoms in 14 of 15 patients.",
"     </li>",
"     <li>",
"      In a second study, patients with RLS had a lower spinal fluid ferritin concentration than age-matched controls (1.11 versus 3.50",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      and a higher spinal fluid transferrin concentration (26.4 versus 6.71",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/42\">",
"       42",
"      </a>",
"      ]. However, there was no difference in serum ferritin and transferrin between the two groups.",
"     </li>",
"     <li>",
"      A study that performed MRI estimates of brain iron concentration in a small number of patients with RLS found significantly reduced iron in the substantia nigra [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/43\">",
"       43",
"      </a>",
"      ]. Compared with controls, another study found evidence that the iron management protein profile at the site of blood-brain interface was altered in patients with RLS, with a decrease in transferrin receptor expression in the microvasculature in the setting of relative brain iron deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neuropathological studies found altered iron management protein levels that were consistent with iron insufficiency in substantia nigra neuromelanin cells from patients with RLS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Quantitative analyses showed decreased levels of ferritin, divalent metal transporter 1 (DMT1), ferroportin, transferrin receptor, and iron regulatory protein 1 (IRP1) compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these findings are not conclusive, they warrant the measurement of serum ferritin levels in patients with RLS and a trial of oral iron therapy when ferritin levels are low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Oral iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral iron therapy may also be considered when ferritin levels are within normal range, as some patients without iron deficiency may still respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;RLS is common among dialysis patients, with a reported incidence of 6 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Anemia may play a role in these circumstances, since low-dose erythropoietin therapy significantly reduced RLS in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, iron therapy among dialysis patients with functional, but not absolute, iron deficiency was beneficial in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14773?source=see_link&amp;anchor=H8#H8\">",
"     \"Uremic polyneuropathy\", section on 'Restless legs syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A third study, however, found that a low serum parathyroid hormone concentration, but not serum hemoglobin, was associated with the presence of RLS in 136 dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;RLS can be a prominent feature of diabetic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], and type 2 diabetes may be an independent risk factor for RLS development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/57\">",
"     57",
"    </a>",
"    ]. RLS and other sensory symptoms of neuropathy often improve following successful pancreatic-kidney transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mounting evidence suggests that RLS is associated with multiple sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]. In a meta-analysis of six cross-sectional studies, individuals with multiple sclerosis had a significantly increased prevalence of RLS compared with individuals without multiple sclerosis (odds ratio 3.77, 95% CI 3.08-4.63) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/63\">",
"     63",
"    </a>",
"    ]. As an example of one of the studies included in the meta-analysis, a prospective multicenter epidemiologic survey of 861 patients with MS and 649 control subjects found that the prevalence of RLS was significantly higher in patients with MS than in controls (19 versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Parkinson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both RLS and Parkinson disease appear to involve disturbances in the dopaminergic neurotransmitter system, suggesting a common mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/64\">",
"     64",
"    </a>",
"    ]. However, few studies have examined the relationship between these two disorders, and progress is hampered by a lack of understanding regarding the pathophysiology of RLS. In contrast to Parkinson disease, preliminary neuropathologic evidence suggests that the pathogenesis of RLS does not involve neuronal degeneration of nigrostriatal pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the prevalence of RLS among patients with Parkinson disease vary widely from 0 to 21 percent; some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/37,65-67\">",
"     37,65-67",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/68-71\">",
"     68-71",
"    </a>",
"    ] studies have found that the prevalence of RLS is higher in patients with Parkinson disease than in the general population. Probably the best data come from a population-based study from Norway of 200 patients with early untreated Parkinson disease who were compared with 173 matched control subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/70\">",
"     70",
"    </a>",
"    ]. The frequency of RLS was nonsignificantly higher in patients with Parkinson disease compared with controls (12.5 versus 9.6 percent, relative risk [RR] 1.76, 95% CI 0.9-3.43). This finding suggests that the overlap of RLS with untreated Parkinson disease is most likely coincidental [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/72\">",
"     72",
"    </a>",
"    ]. However, the issue is not settled. One series found that patients with both Parkinson disease and RLS were older at RLS onset, were less likely to have a family history of RLS, and had lower serum ferritin levels compared with patients with idiopathic RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/37\">",
"     37",
"    </a>",
"    ]. When both disorders were present, Parkinson disease preceded RLS in 68 percent of patients. There are also indications that long-term antiparkinson therapy may contribute to the apparent increased prevalence of RLS in patients with Parkinson disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/66\">",
"     66",
"    </a>",
"    ]. One potential explanation is that wearing-off episodes related to levodopa therapy can be associated with symptoms that mimic RLS, such as unpleasant sensations and the urge to move the legs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/73\">",
"     73",
"    </a>",
"    ]. Another is that prolonged levodopa exposure can induce augmentation of RLS, characterized by increasingly severe symptoms, onset earlier in the day or spread to other body parts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Akathisia, a subjective feeling of motor restlessness accompanied by inability to sit or stand still, is also common in Parkinson disease, with prevalence rates ranging from 26 to 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/68,75\">",
"     68,75",
"    </a>",
"    ] and the potential for overlap with RLS (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/76\">",
"     76",
"    </a>",
"    ]. Due to the similarity of symptoms, some patients with akathisia may be misidentified as having RLS, but the two can be distinguished. As an example, leg motor restlessness, defined as the urge to move the legs in subjects not fulfilling RLS criteria, was an outcome measure in the population-based case-control study cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/70\">",
"     70",
"    </a>",
"    ]. The frequency of leg motor restlessness was significantly higher in patients with Parkinson disease compared with controls (25 versus 8.7 percent, RR 2.84, 95% CI 1.43-5.61) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/70\">",
"     70",
"    </a>",
"    ]. However, the significance of this finding is uncertain, since wearing-off episodes or other effects of antiparkinson medications may contribute to motor restlessness in patients with Parkinson disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy appears to be a risk factor for the occurrence or worsening of RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. In a study of 626 pregnant women admitted to a single center, the diagnosis of RLS was determined by the four International RLS Study group criteria (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Diagnosis'",
"    </a>",
"    below); the prevalence of RLS in this group of women was 10 percent before pregnancy and increased to 27 percent during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/80\">",
"     80",
"    </a>",
"    ]. The highest rates were seen in the third trimester and dropped quickly after delivery. Older studies have reported lower rates of RLS during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/77-79\">",
"     77-79",
"    </a>",
"    ], but none of them had used or strictly applied the four standard diagnostic criteria.",
"   </p>",
"   <p>",
"    The cause of the increased frequency of RLS during pregnancy is unclear, but possible causes include iron deficiency, folate deficiency, and hormonal changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment recommendations for RLS in pregnancy are summarized below (see",
"    <a class=\"local\" href=\"#H37\">",
"     'Treatment in pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rheumatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between RLS and rheumatic disease is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, RLS was present in 25 percent of patients with rheumatoid arthritis compared with 4 percent of controls with osteoarthritis or seronegative arthropathy and was associated with greater disease activity and severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A higher than expected prevalence of RLS has been reported in patients with Sj&ouml;gren's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/83\">",
"       83",
"      </a>",
"      ] and in systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 135 patients with fibromyalgia, 42 had RLS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from a neurology specialty clinic found no evidence of clinical rheumatologic disease among 68 patients with RLS, and only four patients had positive serologies for rheumatic diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Venous insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicose veins have been associated with RLS and treatment of varicose veins and chronic venous insufficiency may be helpful in some patients. As an example, one study found that 312 of 1397 patients seeking treatment for varicose veins had symptoms of RLS on a screening questionnaire and interview [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/87\">",
"     87",
"    </a>",
"    ]. Sclerotherapy was performed in 113 of the patients with RLS; 98 percent reported initial relief of RLS. Symptom relief was maintained in 72 percent at two years of follow-up.",
"   </p>",
"   <p>",
"    Treatment of chronic venous insufficiency with hydroxyethylrutoside also appears to be beneficial in patients with RLS but not as striking or dramatic as sclerotherapy. A meta-analysis of 15 trials that included a total of 1973 patients found that RLS improved in 36 percent of those treated with an average dose of 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for a minimum of four weeks compared with 26 percent of placebo controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=see_link&amp;anchor=H20#H20\">",
"     \"Medical management of lower extremity chronic venous disease\", section on 'Hydroxyethylrutoside'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other miscellaneous conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders that have been reported to be associated with RLS include peripheral neuropathies, amyotrophic lateral sclerosis, vitamin deficiencies, lumbosacral radiculopathy, spinal stenosis, excess caffeine intake, administration of mianserin, hypoglycemia, hypothyroidism, and obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/16,89-96\">",
"     16,89-96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the subjective symptoms of RLS are often difficult to describe, the clinical features are highly stereotyped. The hallmark of RLS is a marked discomfort in the legs that occurs only at rest and is immediately relieved by movement. The abnormal feelings are typically deep seated and localized below the knees. Distribution is usually bilateral, but some asymmetry may occur and the arms can be affected in more severe cases.",
"   </p>",
"   <p>",
"    Terms that patients use to describe the symptoms include crawling, creeping, pulling, itching, drawing, or stretching, all localized to deep structures rather than the skin. Pain and tingling paresthesia of the type that occurs in painful peripheral neuropathy are usually absent, and there is no sensitivity to touching of the skin.",
"   </p>",
"   <p>",
"    Symptoms typically worsen towards the end of the day and are maximal at night, when they appear within 15 to 30 minutes of reclining in bed. In severe cases symptoms may occur earlier in the day while the patient is seated, thereby interfering with attending meetings, sitting in a movie theater, and similar activities. In milder cases patients will fidget, move in bed, and kick or massage their legs for relief. Patients with more severe symptoms feel forced to get out of bed and pace the floor to relieve symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Periodic limb movements of sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic limb movements of sleep (PLMS) are sudden jerking leg movements that commonly accompany RLS. These are repetitive, highly stereotyped movements that typically involve extension of the big toe with partial flexion of the ankle, knee, and sometimes the hip. Each movement lasts approximately 0.5 to 5 seconds and is repeated every 20 to 40 seconds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/97\">",
"     97",
"    </a>",
"    ]. The movements typically occur in clusters lasting several minutes to an hour. The patient is usually unaware of these movements. The prevalence of PLMS increases with age, and PLMS are identified in the vast majority of patients with RLS during sleep laboratory evaluations. Several observational studies have reported an association between PLMS and cardiovascular disease, but the available studies do not address whether there is a causal relationship in either direction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/98-101\">",
"     98-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is not necessary if PLMS occur without sleep complaints.",
"   </p>",
"   <p>",
"    In some patients, however, the periodic limb movements may cause partial or total arousal from sleep and provide an additional cause of insomnia and excessive daytime drowsiness. In such cases, periodic limb movement disorder (PLMD) of sleep is the term used to characterize the association of PLMS and hypersomnolence. A case-control polysomnography study found that 45 patients with RLS had significantly higher indices of sleep fragmentation and of PLMS than 45 matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, treatment of symptomatic PLMD is approached using the same drugs and regimens as are used to treat RLS, particularly when PLMD is accompanied by RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    are often used to treat PLMD in the absence of RLS. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Benzodiazepines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Formal diagnostic criteria for PLMD require polysomnography as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/105\">",
"     105",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is clinical evidence of disturbed sleep or daytime fatigue",
"     </li>",
"     <li>",
"      Polysomnography demonstrates repetitive movements that are 0.5 to 5 seconds in duration, typically separated by an interval of 20 to 40 seconds (range 5 to 90 seconds)",
"     </li>",
"     <li>",
"      There are more than 15 periodic limb movements per hour of sleep time in most adults and more than five per hour of sleep in children",
"     </li>",
"     <li>",
"      The periodic limb movements are not better explained by another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RLS is often delayed or missed, especially when the symptoms are relatively mild or non-specific. The diagnosis of primary RLS rests on typical symptoms in the presence of a normal neurologic examination. Patients with secondary forms of RLS due to peripheral neuropathy may have related sensory and reflex abnormalities.",
"   </p>",
"   <p>",
"    The International Restless Legs Study Group proposed the following four features as essential criteria for the diagnosis of RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/106\">",
"     106",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. Sometimes the urge to move is present without the uncomfortable sensations, and sometimes the arms or other body parts are involved in addition to the legs.",
"     </li>",
"     <li>",
"      The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.",
"     </li>",
"     <li>",
"      The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.",
"     </li>",
"     <li>",
"      The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. When symptoms are severe, the worsening at night may not be noticeable but must have been previously present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive criteria for the diagnosis of RLS include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/106\">",
"     106",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A family history of RLS",
"     </li>",
"     <li>",
"      A positive response to dopaminergic drugs",
"     </li>",
"     <li>",
"      Periodic limb movements during wakefulness or sleep as assessed with polysomnography or leg activity devices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polysomnography in a sleep laboratory is not necessary for the diagnosis, but it may be helpful, especially when RLS is resistant to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Periodic limb movements of sleep'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis begins with separating primary from secondary RLS. Iron deficiency and renal failure are particularly important to exclude; a normal hemoglobin does not rule out iron deficiency if the serum ferritin is low. Peripheral neuropathy, lumbosacral radiculopathy, and ordinary leg cramps, all of which are typically more painful conditions, should also be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=see_link\">",
"     \"Nocturnal leg cramps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RLS should be differentiated from akathisia, a common side effect of the phenothiazine antipsychotic drugs and selective serotonin reuptake inhibitor (SSRI) antidepressants. Akathisia (from the Greek \"not to sit\") is a more constant and generalized feeling of motor restlessness unassociated with subjective discomfort localizing to the legs. In contrast to akathisia, RLS has a circadian rhythm (worse at night when the patient is sitting or in bed) and is commonly accompanied by paresthesia and myoclonic jerks during the waking state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/108\">",
"     108",
"    </a>",
"    ]. The syndrome of \"painful legs and moving toes\" is a rare disorder of unknown cause characterized by more prominent involuntary toe movements and leg pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/109\">",
"     109",
"    </a>",
"    ]. Other conditions that may mimic RLS include partial myoclonic jerks, massive myoclonic jerks (hypnic jerks), and periodic movements of sleep. Partial myoclonic jerks are usually multifocal and occur in distal muscles. Massive myoclonic jerks are generalized and affect trunk and proximal muscles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7689?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification and evaluation of myoclonus\", section on 'Jerks associated with sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of treatments for RLS have been studied in primarily small, randomized, controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/48,110-112\">",
"     48,110-112",
"    </a>",
"    ]. Placebo controlled studies are particularly important since RLS is normally characterized by fluctuations and remissions.",
"   </p>",
"   <p>",
"    Iron replacement therapy is suggested for all patients with RLS. Nonpharmacologic measures such as mental alerting activities, avoidance of aggravating factors, stretching exercises for the posterior leg muscles, heat (warm baths or heating pad), and massage may be helpful for some patients with RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacotherapy for idiopathic RLS with benzodiazepines, dopaminergic drugs, or, in resistant cases, opioids have been successful in many patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/114\">",
"     114",
"    </a>",
"    ]. Dopaminergic drugs such as levodopa (L-dopa) and dopamine agonists appear to be more effective than benzodiazepines in patients with RLS, although there are no direct comparison studies. (See",
"    <a class=\"local\" href=\"#H102960803\">",
"     'Levodopa'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Pramipexole and ropinirole'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Expert panel recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An algorithm for the management of RLS devised by an expert panel highlights three particular types of RLS (intermittent, daily, and refractory) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. Recommendations for these three types are excerpted here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Intermittent RLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent RLS is defined as RLS that is troublesome enough when present to require treatment but that is not sufficiently frequent to require regular daily medication use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. Treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonpharmacologic therapy (see",
"      <a class=\"local\" href=\"#H102960355\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Levodopa (see",
"      <a class=\"local\" href=\"#H102960803\">",
"       'Levodopa'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Dopamine agonists (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Dopamine agonists'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Low potency opioids or opioid agonists (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Opioids'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Benzodiazepines or benzodiazepine agonists (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Benzodiazepines'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Daily RLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily RLS is defined as RLS that is frequent and troublesome enough to require daily treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. Treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonpharmacologic therapy (see",
"      <a class=\"local\" href=\"#H102960355\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Dopamine agonists (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Dopamine agonists'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H102960195\">",
"       'Gabapentin'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Low potency opioids or opioid agonists (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Opioids'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Refractory RLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory RLS is defined as daily RLS treated with a dopamine agonist but with a poor response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. The response is considered poor if there is an inadequate initial response despite adequate doses of medication or if the response becomes inadequate with time despite increasing doses. Augmentation (the onset of symptoms earlier in the day or extension of symptoms to arms or trunk) that is not controllable with additional earlier doses of the drug also qualifies RLS as refractory, as does intolerable adverse effects.",
"   </p>",
"   <p>",
"    Referral to a specialist for RLS management should be considered for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. Four different pharmacologic treatment approaches are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Change to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"     </li>",
"     <li>",
"      Change to a different dopamine agonist",
"     </li>",
"     <li>",
"      Add a second agent such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , a benzodiazepine, or an opioid",
"     </li>",
"     <li>",
"      Change to a high potency opioid or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102960355\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapy is recommended by the expert panel for patients with intermittent or daily RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. The therapy involves the following components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113,115,116\">",
"     113,115,116",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Iron replacement therapy",
"     </li>",
"     <li>",
"      Mental alerting activities",
"     </li>",
"     <li>",
"      Avoidance of aggravating factors",
"     </li>",
"     <li>",
"      Short daily hemodialysis for patients in renal failure",
"     </li>",
"     <li>",
"      Exercise",
"     </li>",
"     <li>",
"      Leg message",
"     </li>",
"     <li>",
"      Heat applied by heating pads or hot baths",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Online information and support is available for patients with RLS through",
"    <a class=\"external\" href=\"file://www.rls.org/\">",
"     The Restless Legs Syndrome Foundation",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102960405\">",
"    <span class=\"h3\">",
"     Iron replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of oral iron therapy is",
"    <strong>",
"     suggested",
"    </strong>",
"    for all patients with RLS, particularly premenopausal women, as some patients without evidence of iron deficiency may still respond favorably [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/48\">",
"     48",
"    </a>",
"    ]. An exception is patients with iron overload syndromes (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    ), who should not be treated with iron. Iron replacement is",
"    <strong>",
"     recommended",
"    </strong>",
"    if the serum ferritin level is lower than 45 to 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (45 to 50",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    suggested iron therapy regimen is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    (325 mg two to three times a day) in combination with vitamin C (100 to 200 mg with each dose of ferrous sulfate) to enhance absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Oral iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ferritin levels should be checked after three to four months of therapy and then every three to six months until the serum ferritin level is &gt;50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (&gt;50",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    and iron saturation is greater than 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102960441\">",
"    <span class=\"h3\">",
"     Avoidance of aggravating drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine, nicotine, and alcohol may aggravate RLS symptoms. A trial of abstinence is reasonable in many patients.",
"   </p>",
"   <p>",
"    Antidepressants, neuroleptic agents, dopamine-blocking antiemetics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , or sedating antihistamines (including those found in nonprescription medications) may contribute to RLS symptoms. However, discontinuation may not be possible without causing patient harm. If antidepressants are necessary, the symptoms of secondary RLS can usually be treated in the same way as primary RLS.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is an alternative antidepressant that may be less likely to induce or worsen RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102960448\">",
"    <span class=\"h3\">",
"     Short daily hemodialysis for patients in renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective cohort study (FREEDOM study) that included 94 patients with disturbed sleep",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restless leg syndrome, short daily hemodialysis resulted in a sustained improvement in restless legs symptoms as assessed by the International Restless Leg Syndrome Study Group rating scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/118\">",
"     118",
"    </a>",
"    ]. However the percentage of patients prescribed medication for restless leg syndrome did not decrease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=see_link&amp;anchor=H21#H21\">",
"     \"Short daily hemodialysis\", section on 'Quality of life'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonists belong to a class of drugs that directly stimulate dopamine receptors and have a longer half-life (four to six hours) than levodopa (90 minutes). They are generally superior to levodopa for the treatment of daily RLS. In a 2011 meta-analysis of 38 trials evaluating dopamine agonists for the treatment of RLS that included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    , lisuride, pergolide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/45/5846?source=see_link\">",
"     rotigotine",
"    </a>",
"    , and sumanirole, all except sumanirole were superior to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/110\">",
"     110",
"    </a>",
"    ]. In two trials, cabergoline and pramipexole were superior to levodopa for improvement in disease severity as measured by the International Restless Leg Syndrome Study Group rating scale (IRLS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pramipexole and ropinirole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-ergot dopamine agonists,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    , are less likely to cause side effects than other dopamine agonists. These agents are considered to be the drugs of choice in most patients with daily RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. They may also be helpful in patients with intermittent RLS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      for RLS was demonstrated in three similar randomized controlled trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/119-121\">",
"       119-121",
"      </a>",
"      ]. As an example, one of these trials enrolled 284 patients with moderate to severe RLS; improvement on the primary outcome measure of symptoms as assessed by the International Restless Legs Syndrome Study Group rating scale (IRLS) was significantly greater for ropinirole treatment (average dose 1.13",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      than for placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      was demonstrated in a 12-week double-blind trial that assigned 344 patients with moderate or severe RLS to one of three pramipexole regimens (0.25, 0.50, and 0.75",
"      <span class=\"nowrap\">",
"       mg/daily)",
"      </span>",
"      or to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/122\">",
"       122",
"      </a>",
"      ]. The initial pramipexole dose was 0.125",
"      <span class=\"nowrap\">",
"       mg/daily",
"      </span>",
"      for the first week, and the dose was titrated up to the assigned dose over the first three weeks of the trial. All three doses of pramipexole were superior to placebo on the two primary outcome measures (patient-rated symptom severity improvement measured by the IRLS, and clinician-rated improvement). Pramipexole was well tolerated; nausea and somnolence were the most frequent side effects associated with its use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    are usually mild, transient, and limited to nausea, lightheadedness, and fatigue; these usually resolve within 10 to 14 days. Less frequent side effects include nasal stuffiness, constipation, insomnia, and leg edema; these are reversible if the medication is stopped. Sudden, unexpected sleep attacks, as described in patients with Parkinson disease on higher doses of pramipexole, do not appear to occur in patients on low-dose pramipexole (mean of 0.37",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As first reported in patients with Parkinson disease, dopamine agonist therapy in patients with RLS may be associated with an increased risk of impulse control disorders such as pathologic gambling, compulsive eating and shopping, and inappropriate hypersexuality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Impulse control disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The onset of action for dopamine agonists is typically 90 to 120 minutes after intake. Therefore, these medications should be started two hours before RLS symptoms start [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. The recommended starting doses are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       Pramipexole",
"      </a>",
"      0.125 mg once daily. The dose may be increased by 0.125 mg every two to three days until relief is obtained. In a clinical trial, all three doses of pramipexole (0.25, 0.50, and 0.75",
"      <span class=\"nowrap\">",
"       mg/daily)",
"      </span>",
"      were equally effective, and some patients responded to the initial dose of 0.125 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/122\">",
"       122",
"      </a>",
"      ]. However, side effects were more common with the 0.50 mg and 0.75 mg daily. Therefore, it is expected that 0.25 mg daily has the best therapeutic margin. Most patients require 0.5 mg or less, but doses up to 2 mg may be needed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       Ropinirole",
"      </a>",
"      0.25 mg once daily. The dose may be increased by 0.25 mg every two to three days until relief is obtained. Most patients require 2 mg or less, but doses up to 4 mg or higher may be needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Augmentation is less common with these drugs than with levodopa, but it has been reported in up to one-third of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. The risk of augmentation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. In one study, augmentation was significantly more common in patients with a family history of restless legs syndrome and in those who had no evidence of neuropathy on electromyography or nerve conduction studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike levodopa, additional doses of a dopamine agonist earlier in the day can often reduce the risk and intensity of augmentation, which is a worsening of RLS symptoms earlier in the day after an evening dose of medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. The development of augmentation with one dopamine agonist does not necessarily predict augmentation with a different agonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/125\">",
"     125",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    can be substituted for one another. However, therapy should be changed to a different class of medications if augmentation develops with a second dopamine agonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other dopamine agonists are also effective in RLS but are used infrequently.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       Cabergoline",
"      </a>",
"      (0.5 to 4 mg as an evening dose) is a dopamine agonist with a long half-life (65 hours) that may benefit patients who experience rebound symptoms with shorter half-life medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/89,128,129\">",
"       89,128,129",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a five-week randomized clinical trial of 85 patients with RLS,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      at doses of 0.5, 1.0, and 2.0",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (taken at least three hours before bedtime) was effective compared with placebo in treating RLS symptoms and sleep disturbance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/130\">",
"       130",
"      </a>",
"      ]. In an open-label, one-year extension, a mean daily dose of cabergoline 2.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      was required to maintain improvement of RLS symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A later five-week randomized controlled trial of 40 patients with moderate to severe RLS found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      2 mg once daily in the evening was significantly more effective than placebo by polysomnography for reducing PLMS-related arousal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Side effects in the first trial including nausea, constipation, headache, dizziness, fatigue, and drowsiness caused treatment discontinuation in 11 patients (13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/130\">",
"       130",
"      </a>",
"      ]. Augmentation (the onset of symptoms earlier in the day or extension of symptoms to arms or trunk) was observed in six treated patients (9 percent) in the long-term phase. In a study of patients with Parkinson disease, high cumulative dose and long-term treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      was associated with an increased risk of cardiac valvulopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pergolide was effective for relieving symptoms of RLS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/110\">",
"       110",
"      </a>",
"      ]. However, pergolide was associated with restrictive cardiac valve disease in 33 percent of patients when used in high doses to treat PD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/133\">",
"       133",
"      </a>",
"      ]. Because of this association, pergolide was voluntarily withdrawn from the United States market in 2007 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102960803\">",
"    <span class=\"h2\">",
"     Levodopa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of levodopa (levodopa) for restless legs syndrome has been demonstrated in small randomized trials and a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/135\">",
"     135",
"    </a>",
"    ]. The following trials illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one double-blind, crossover study lasting four weeks, an evening dose of levodopa 200 mg with benserazide (a peripheral dopa decarboxylase inhibitor used in Europe and equivalent to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"       carbidopa",
"      </a>",
"      used in the United States) significantly reduced the frequency of awakenings and duration of waking periods in 13 patients with RLS compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second double-blind trial in which 20 patients with RLS were given levodopa, 50 to 200 mg daily with benserazide or lactose on alternate days for an unspecified period of time, 17 patients reported complete relief with levodopa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levodopa was also effective in a double-blind study of uremic RLS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tachyphylaxis (a decreasing response with continual treatment) to levodopa has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/139\">",
"     139",
"    </a>",
"    ], but in one long-term study lasting two years, 26 of 30 patients initially responding to levodopa maintained a good response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three different problems may occur with patients on levodopa therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Augmentation is a worsening of RLS symptoms earlier in the day after an evening dose of medication, including earlier onset of symptoms, increased intensity of symptoms, or spread of symptoms to the arms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/141\">",
"       141",
"      </a>",
"      ]. It occurs in up to 70 percent of patients taking daily levodopa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/142\">",
"       142",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rebound is the recurrence of RLS early in the morning. It occurs in 20 to 35 percent of patients taking levodopa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/139,142\">",
"       139,142",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrence of symptoms in the second half of the night may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An expert advisory panel on RLS recommends levodopa only for intermittent RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. The risk of augmentation may be decreased with intermittent use of dopaminergic drugs, although this has not been well studied. The expert panel recommends discontinuation of the drug if augmentation occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. Controlled release levodopa (CR) combined with standard levodopa may help sleep quality during the second half of the night for patients who experience recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For best absorption, levodopa should not be taken with high protein foods. Suggested agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"       Carbidopa-levodopa",
"      </a>",
"      25",
"      <span class=\"nowrap\">",
"       mg/100",
"      </span>",
"      mg, one-half or one tablet, can be used for intermittent RLS that occurs during the evening, at bedtime, or on waking during the night. Additionally, this medication may be helpful for RLS associated with specific triggers including lengthy travel by auto or airline, or spectator events with prolonged sitting.",
"     </li>",
"     <li>",
"      Controlled release (CR)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/36/36423?source=see_link\">",
"       carbidopa-levodopa",
"      </a>",
"      , 25",
"      <span class=\"nowrap\">",
"       mg/100",
"      </span>",
"      mg before bed may be helpful for RLS that awakens the patient during the night.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are useful in mild cases of RLS, particularly in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/144,145\">",
"     144,145",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    has been used in RLS for many years, although there have been no controlled trials. In a small randomized, double-blind, crossover trial, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    , 1.0 mg daily, was superior to placebo in six patients with RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/146\">",
"     146",
"    </a>",
"    ]. In an open trial, 14 of 15 patients with RLS due to uremia responded to clonazepam, 1 to 2 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/147\">",
"     147",
"    </a>",
"    ]. Clinical experience suggests that clonazepam is useful in some patients at 0.5 mg daily.",
"   </p>",
"   <p>",
"    An RLS expert panel algorithm recommends benzodiazepines or benzodiazepine agonists for intermittent RLS, especially if the patient has another cause of poor sleep in addition to RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. Short-acting agents can be helpful for sleep onset insomnia caused by RLS; these agents include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/49/23319?source=see_link\">",
"       Triazolam",
"      </a>",
"      0.125 to 0.5 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/48/13064?source=see_link\">",
"       Zolpidem",
"      </a>",
"      5 to 10 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/61/15318?source=see_link\">",
"       Zaleplon",
"      </a>",
"      5 to 10 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For RLS that awakens the patient later in the night, the expert panel recommends intermediate acting agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    15 to 30 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most trials have been performed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    , its long duration of action may result in more adverse effects, such as nocturnal unsteadiness and drowsiness or cognitive impairment in the morning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. However, at least one study has shown a low rate of adverse effects from clonazepam in elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term maintenance treatment with benzodiazepines is limited by tolerance in many patients, but abuse appears to be low in this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102960195\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    and the extended release formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/12/1222?source=see_link\">",
"     gabapentin enacarbil",
"    </a>",
"    are alternative choices for patients with daily RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113,148,149\">",
"     113,148,149",
"    </a>",
"    ]. Gabapentin, mean dose 733",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    was effective in a four-week open-label study of nine patients with idiopathic RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/150\">",
"     150",
"    </a>",
"    ], and at a much higher mean dose (1,855 mg) in a randomized, placebo-controlled trial of 22 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/151\">",
"     151",
"    </a>",
"    ]. Among dialysis patients, gabapentin (200 to 300 mg three times weekly after hemodialysis) was effective in a 12-week, double-blind crossover study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the trial data above suggest that mean doses of 1800 mg a day are needed, many patients appear to benefit from a lower dose. The expert panel suggests beginning treatment with 100 to 300 mg per dose because of the tendency of the drug to cause somnolence and gait unsteadiness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    may be particularly useful in patients whose symptoms are less intense and in patients in whom RLS is perceived as painful. It may also be useful when RLS occurs in the setting of a painful peripheral neuropathy or an unrelated chronic pain syndrome. Gabapentin may also be considered in the treatment of RLS in association with neurodegenerative disorders, such as PD or dementia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of opioids, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , have been reported to be helpful for RLS in uncontrolled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/153\">",
"     153",
"    </a>",
"    ]. In a double-blind, four week crossover study of 11 patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    at a mean dose 15.9",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    was superior to placebo with regard to number of sleep arousals, PLMS frequency, and sleep efficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/154\">",
"     154",
"    </a>",
"    ]. One long-term retrospective study of 113 patients treated with opioids has shown persistent benefit, but a small number of patients developed sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to benzodiazepines, opioid abuse potential is low in patients with RLS. Nevertheless, we typically restrict use to patients with more severe symptoms who fail to respond to benzodiazepines or dopaminergic drugs.",
"   </p>",
"   <p>",
"    The expert RLS panel recommends more liberal use of low potency opioids or opioid agonists for intermittent RLS and as an alternative for daily RLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. These drugs are usually taken before bed and include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       Codeine",
"      </a>",
"      30 to 60 mg, usually in combination preparations with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"      50 to 100 mg before bed or during the night",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with refractory RLS, the same panel recommends change to a high potency opioid or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    as one of four different management approaches (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Refractory RLS'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]. High potency opioids may be effective in the management of RLS, and escalation of doses and dependence are uncommon in the absence of a history of substance abuse. High potency opioids may be used one to three times a day depending on timing of symptoms; agents include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       Oxycodone",
"      </a>",
"      5 to 15 mg",
"     </li>",
"     <li>",
"      Hydrocodone 5 to 15 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      5 to 10 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"      50 to 100 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    (starting dose 150",
"    <span class=\"nowrap\">",
"     mg/daily,",
"    </span>",
"    mean dose 337",
"    <span class=\"nowrap\">",
"     mg/daily)",
"    </span>",
"    was superior to placebo for improving symptoms of RLS in a 12-week randomized controlled trial of 58 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/156\">",
"     156",
"    </a>",
"    ]. Other drugs that may be useful in RLS but have been reported in only a small number of mainly open studies include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    (mean dose 236",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/157\">",
"     157",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    (0.05",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/158\">",
"     158",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (40 to 120",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/159\">",
"     159",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    (up to 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/50/32554/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/29/20946?source=see_link\">",
"       \"Patient information: Restless legs syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for RLS treatment by the expert panel are listed above (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Expert panel recommendations'",
"    </a>",
"    above). We recommend the following sequence of pharmacologic therapy in patients with RLS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of oral iron therapy is suggested for all patients with RLS (except those with iron overload), particularly premenopausal women, as some patients without evidence of iron deficiency may still respond favorably. (See",
"      <a class=\"local\" href=\"#H102960405\">",
"       'Iron replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Begin pharmacologic treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      (0.125 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      (0.25 mg) approximately one hour before the usual time of symptom onset; the dose is titrated upward according to response. These drugs are effective and well tolerated by most patients. Pramipexole doses above 0.75",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and ropinirole doses above 4",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      are of unproven benefit. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Pramipexole and ropinirole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative is",
"      <span class=\"nowrap\">",
"       levodopa/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3221?source=see_link\">",
"        carbidopa",
"       </a>",
"       ,",
"      </span>",
"      <span class=\"nowrap\">",
"       25/100",
"      </span>",
"      mg given before symptom onset in patients unable to tolerate a dopamine agonist. In some cases a controlled release formulation of levodopa may be necessary to get the patient through the night or to avoid rebound daytime symptoms. (See",
"      <a class=\"local\" href=\"#H102960803\">",
"       'Levodopa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"       Clonazepam",
"      </a>",
"      starting at 0.5 mg before sleep can be used alone or as adjunctive treatment.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      may be a good additional option because of its relative lack of adverse and sedative effects.",
"     </li>",
"     <li>",
"      Opioids should be reserved as a final option, either alone or in conjunction with other medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination therapy is often useful, and periodic changes in choice of medication to deal with tolerance are frequently necessary. In some patients, additional doses of medication may be necessary during the day to manage diurnal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Treatment in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of RLS in pregnant women is complicated by the fact that nearly all of the drugs used for RLS are considered pregnancy risk factor C or D (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). The one major exception is pergolide, which has other serious side effects (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Other dopamine agonists'",
"    </a>",
"    above). The following options are therefore suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opioids (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Opioids'",
"      </a>",
"      above) can be used in the second or third trimester if treatment of RLS symptoms is necessary. The lowest effective dose of opioids should be used for the shortest period of time to reduce the risk of neonatal withdrawal. In most patients, RLS begins in the third trimester of pregnancy and disappears toward the end of the pregnancy (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Pregnancy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Oral iron supplements should be maintained since it appears that women with RLS in pregnancy have lower hemoglobin and mean corpuscular volume than healthy subjects (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Pregnancy'",
"      </a>",
"      above). In exceptional cases, parenteral iron therapy is a consideration (see",
"      <a class=\"local\" href=\"#H102960405\">",
"       'Iron replacement'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Nonpharmacologic therapy (see",
"      <a class=\"local\" href=\"#H102960355\">",
"       'Nonpharmacologic therapy'",
"      </a>",
"      above) should be tried if RLS symptoms occur earlier than the third trimester. Leg stretching before sleep and use of elastic stockings may also be helpful. Elastic stockings or sclerotherapy should be considered if varicose veins are prominent.",
"     </li>",
"     <li>",
"      The patient should be counseled regarding the benign nature of the problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most drugs for RLS are not recommended or are not rated by the American Academy of Pediatrics for use during breast feeding.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     Codeine",
"    </a>",
"    is considered compatible with breast feeding but should be used with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/9/15506?source=see_link\">",
"       \"Patient information: Nocturnal (nighttime) leg cramps (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9273048\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Robert Sheon, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/1\">",
"      O'Keeffe ST. Restless legs syndrome. A review. Arch Intern Med 1996; 156:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/2\">",
"      Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994; 17:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/3\">",
"      Nichols DA, Allen RP, Grauke JH, et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med 2003; 163:2323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/4\">",
"      H&ouml;gl B, Kiechl S, Willeit J, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005; 64:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/5\">",
"      Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011; 26:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/6\">",
"      Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/7\">",
"      Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/8\">",
"      Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004; 164:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/9\">",
"      Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: prevalence and impact in children and adolescents--the Peds REST study. Pediatrics 2007; 120:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/10\">",
"      Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996; 46:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/11\">",
"      Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol 2004; 56:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/12\">",
"      Pullen SJ, Wall CA, Angstman ER, et al. Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study. J Clin Sleep Med 2011; 7:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/13\">",
"      Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/14\">",
"      Winkelmann J, Prager M, Lieb R, et al. \"Anxietas tibiarum\". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol 2005; 252:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/15\">",
"      Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs 2010; 24:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/16\">",
"      Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 1999; 22:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/17\">",
"      Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/18\">",
"      Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000; 55:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/19\">",
"      Pichler I, Marroni F, Volpato CB, et al. Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet 2006; 79:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/20\">",
"      Chen S, Ondo WG, Rao S, et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 2004; 74:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/21\">",
"      Lohmann-Hedrich K, Neumann A, Kleensang A, et al. Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology 2008; 70:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/22\">",
"      Desautels A, Turecki G, Montplaisir J, et al. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001; 69:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/23\">",
"      Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 2005; 62:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/24\">",
"      Bonati MT, Ferini-Strambi L, Aridon P, et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003; 126:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/25\">",
"      Levchenko A, Provost S, Montplaisir JY, et al. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology 2006; 67:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/26\">",
"      Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007; 39:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/27\">",
"      Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008; 40:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/28\">",
"      Yang Q, Li L, Yang R, et al. Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome. Mov Disord 2011; 26:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/29\">",
"      Stefansson H, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/30\">",
"      Sch&ouml;ls L, Haan J, Riess O, et al. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 1998; 51:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/31\">",
"      Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity. Neurology 1999; 52:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/32\">",
"      Clemens S, Rye D, Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006; 67:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/33\">",
"      Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/34\">",
"      Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/35\">",
"      Cervenka S, P&aring;lhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006; 129:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/36\">",
"      Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/37\">",
"      Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002; 59:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/38\">",
"      Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002; 25:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/39\">",
"      Allen RP, Mignot E, Ripley B, et al. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 2002; 59:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/40\">",
"      EKBOM KA. Restless legs syndrome. Neurology 1960; 10:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/41\">",
"      O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994; 23:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/42\">",
"      Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000; 54:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/43\">",
"      Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001; 56:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/44\">",
"      Silber MH, Richardson JW. Multiple blood donations associated with iron deficiency in patients with restless legs syndrome. Mayo Clin Proc 2003; 78:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/45\">",
"      Connor JR, Ponnuru P, Wang XS, et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011; 134:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/46\">",
"      Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/47\">",
"      Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004; 62:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/48\">",
"      Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome. Cochrane Database Syst Rev 2012; 5:CD007834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/49\">",
"      Walker S, Fine A, Kryger MH. Sleep complaints are common in a dialysis unit. Am J Kidney Dis 1995; 26:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/50\">",
"      Thorp ML. Restless legs syndrome. Int J Artif Organs 2001; 24:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/51\">",
"      Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004; 43:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/52\">",
"      Harris DC, Chapman JR, Stewart JH, et al. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med 1991; 21:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/53\">",
"      Sloand JA, Shelly MA, Feigin A, et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/54\">",
"      Collado-Seidel V, Kohnen R, Samtleben W, et al. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998; 31:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/55\">",
"      O'Hare JA, Abuaisha F, Geoghegan M. Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci 1994; 163:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/56\">",
"      Lopes LA, Lins Cde M, Adeodato VG, et al. Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care 2005; 28:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/57\">",
"      Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 2007; 30:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/58\">",
"      M&uuml;ller-Felber W, Landgraf R, Wagner S, et al. Follow-up study of sensory-motor polyneuropathy in type 1 (insulin-dependent) diabetic subjects after simultaneous pancreas and kidney transplantation and after graft rejection. Diabetologia 1991; 34 Suppl 1:S113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/59\">",
"      Auger C, Montplaisir J, Duquette P. Increased frequency of restless legs syndrome in a French-Canadian population with multiple sclerosis. Neurology 2005; 65:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/60\">",
"      Italian REMS Study Group, Manconi M, Ferini-Strambi L, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 2008; 31:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/61\">",
"      Deriu M, Cossu G, Molari A, et al. Restless legs syndrome in multiple sclerosis: a case-control study. Mov Disord 2009; 24:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/62\">",
"      G&oacute;mez-Choco MJ, Iranzo A, Blanco Y, et al. Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis. Mult Scler 2007; 13:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/63\">",
"      Li Y, Munger KL, Batool-Anwar S, et al. Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women. Neurology 2012; 78:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/64\">",
"      Garcia-Borreguero D, Odin P, Serrano C. Restless legs syndrome and PD: a review of the evidence for a possible association. Neurology 2003; 61:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/65\">",
"      Krishnan PR, Bhatia M, Behari M. Restless legs syndrome in Parkinson's disease: a case-controlled study. Mov Disord 2003; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/66\">",
"      Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord 2009; 24:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/67\">",
"      Guerreiro TM, Nishikawa DR, Ferreira LC, et al. Restless legs syndrome in Parkinson's disease: clinical characteristics and biochemical correlations. Arq Neuropsiquiatr 2010; 68:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/68\">",
"      Lang AE, Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/69\">",
"      Tan EK, Lum SY, Wong MC. Restless legs syndrome in Parkinson's disease. J Neurol Sci 2002; 196:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/70\">",
"      Gjerstad MD, Tysnes OB, Larsen JP. Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 2011; 77:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/71\">",
"      Angelini M, Negrotti A, Marchesi E, et al. A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: absence of co-morbid association. J Neurol Sci 2011; 310:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/72\">",
"      Arnulf I, Morgan J. Not all that goes \"bump in the night\" is RLS: leg motor restlessness in PD. Neurology 2011; 77:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/73\">",
"      Peralta CM, Frauscher B, Seppi K, et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2009; 24:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/74\">",
"      Garc&iacute;a-Borreguero D, Allen RP, Benes H, et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007; 22 Suppl 18:S476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/75\">",
"      Comella CL, Goetz CG. Akathisia in Parkinson's disease. Mov Disord 1994; 9:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/76\">",
"      Poewe W, H&ouml;gl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004; 63:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/77\">",
"      Ekbom KA. Restless legs syndrome. Acta Med Scan Suppl 1945; 158:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/78\">",
"      Goodman JD, Brodie C, Ayida GA. Restless leg syndrome in pregnancy. BMJ 1988; 297:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/79\">",
"      Suzuki K, Ohida T, Sone T, et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003; 26:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/80\">",
"      Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology 2004; 63:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/81\">",
"      Dzaja A, Wehrle R, Lancel M, Pollm&auml;cher T. Elevated estradiol plasma levels in women with restless legs during pregnancy. Sleep 2009; 32:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/82\">",
"      Salih AM, Gray RE, Mills KR, Webley M. A clinical, serological and neurophysiological study of restless legs syndrome in rheumatoid arthritis. Br J Rheumatol 1994; 33:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/83\">",
"      Gudbj&ouml;rnsson B, Broman JE, Hetta J, H&auml;llgren R. Sleep disturbances in patients with primary Sj&ouml;gren's syndrome. Br J Rheumatol 1993; 32:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/84\">",
"      Hassan N, Pineau CA, Clarke AE, et al. Systemic lupus and risk of restless legs syndrome. J Rheumatol 2011; 38:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/85\">",
"      Yunus MB, Aldag JC. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 1996; 312:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/86\">",
"      Ondo W, Tan EK, Mansoor J. Rheumatologic serologies in secondary restless legs syndrome. Mov Disord 2000; 15:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/87\">",
"      Kanter AH. The effect of sclerotherapy on restless legs syndrome. Dermatol Surg 1995; 21:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/88\">",
"      Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994; 23:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/89\">",
"      Chaudhuri KR, Appiah-Kubi LS, Trenkwalder C. Restless legs syndrome. J Neurol Neurosurg Psychiatry 2001; 71:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/90\">",
"      Lutz EG. Restless legs, anxiety and caffeinism. J Clin Psychiatry 1978; 39:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/91\">",
"      LaBan MM, Viola SL, Femminineo AF, Taylor RS. Restless legs syndrome associated with diminished cardiopulmonary compliance and lumbar spinal stenosis--a motor concomitant of \"Vesper's curse\". Arch Phys Med Rehabil 1990; 71:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/92\">",
"      Markkula J, Lauerma H. Mianserin and restless legs. Int Clin Psychopharmacol 1997; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/93\">",
"      Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology 2009; 72:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/94\">",
"      Gao X, Schwarzschild MA, Wang H, Ascherio A. Obesity and restless legs syndrome in men and women. Neurology 2009; 72:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/95\">",
"      Rajabally YA, Shah RS. Restless legs syndrome in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2010; 42:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/96\">",
"      Limousin N, Blasco H, Corcia P, et al. The high frequency of restless legs syndrome in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011; 12:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/97\">",
"      Karatas M. Restless legs syndrome and periodic limb movements during sleep: diagnosis and treatment. Neurologist 2007; 13:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/98\">",
"      Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009; 32:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/99\">",
"      Coelho FM, Georgsson H, Narayansingh M, et al. Higher prevalence of periodic limb movements of sleep in patients with history of stroke. J Clin Sleep Med 2010; 6:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/100\">",
"      Yumino D, Wang H, Floras JS, et al. Relation of periodic leg movements during sleep and mortality in patients with systolic heart failure. Am J Cardiol 2011; 107:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/101\">",
"      Koo BB, Blackwell T, Ancoli-Israel S, et al. Association of incident cardiovascular disease with periodic limb movements during sleep in older men: outcomes of sleep disorders in older men (MrOS) study. Circulation 2011; 124:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/102\">",
"      Hornyak M, Feige B, Voderholzer U, et al. Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study. Sleep 2007; 30:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/103\">",
"      Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004; 27:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/104\">",
"      Lesage S, Hening WA. The restless legs syndrome and periodic limb movement disorder: a review of management. Semin Neurol 2004; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, Westchester, IL, American Academy of Sleep Medicine, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/106\">",
"      Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/107\">",
"      Chesson A Jr, Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2000; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/108\">",
"      Walters AS, Hening W, Rubinstein M, Chokroverty S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep 1991; 14:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/109\">",
"      Dressler D, Thompson PD, Gledhill RF, Marsden CD. The syndrome of painful legs and moving toes. Mov Disord 1994; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/110\">",
"      Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 2011; :CD006009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/111\">",
"      Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep 2012; 35:1039.",
"     </a>",
"    </li>",
"    <li>",
"     Wilt TJ, MacDonald R, Ouellette J, et al. Treatment for restless legs syndrome. Agency for Healthcare Research and Quality (US). www.ncbi.nlm.nih.gov/books/NBK115385/ (Accessed on January 22, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/113\">",
"      Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004; 79:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/114\">",
"      Earley CJ. Clinical practice. Restless legs syndrome. N Engl J Med 2003; 348:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/115\">",
"      Leschziner G, Gringras P. Restless legs syndrome. BMJ 2012; 344:e3056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/116\">",
"      Mitchell UH. Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome. Neuropsychiatr Dis Treat 2011; 7:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/117\">",
"      Nofzinger EA, Fasiczka A, Berman S, Thase ME. Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000; 61:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/118\">",
"      Jaber BL, Schiller B, Burkart JM, et al. Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 2011; 6:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/119\">",
"      Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004; 75:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/120\">",
"      Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004; 19:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/121\">",
"      Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006; 81:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/122\">",
"      Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/123\">",
"      Stiasny K, M&ouml;ller JC, Oertel WH. Safety of pramipexole in patients with restless legs syndrome. Neurology 2000; 55:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/124\">",
"      Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/125\">",
"      Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003; 26:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/126\">",
"      Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004; 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/127\">",
"      Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004; 61:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/128\">",
"      Stiasny K, R&ouml;bbecke J, Sch&uuml;ler P, Oertel WH. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial. Sleep 2000; 23:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/129\">",
"      Chaudhuri KR. Restless legs syndrome. N Engl J Med 2003; 349:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/130\">",
"      Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004; 63:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/131\">",
"      Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006; 67:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/132\">",
"      Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006; 67:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/133\">",
"      Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Announces Voluntary Withdrawal of Pergolide Products. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108877.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/135\">",
"      Scholz H, Trenkwalder C, Kohnen R, et al. Levodopa for restless legs syndrome. Cochrane Database Syst Rev 2011; :CD005504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/136\">",
"      Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987; 10:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/137\">",
"      von Scheele C. Levodopa in restless legs. Lancet 1986; 2:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/138\">",
"      Trenkwalder C, Stiasny K, Pollm&auml;cher T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995; 18:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/139\">",
"      Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993; 43:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/140\">",
"      von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990; 47:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/141\">",
"      Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996; 19:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/142\">",
"      Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996; 19:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/143\">",
"      Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999; 52:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/144\">",
"      Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996; 100:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/145\">",
"      Montplaisir J, Godbout R, Boghen D, et al. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study. Neurology 1985; 35:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/146\">",
"      Montagna P, Sassoli de Bianchi L, Zucconi M, et al. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984; 69:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/147\">",
"      Read DJ, Feest TG, Nassim MA. Clonazepam: effective treatment for restless legs syndrome in uraemia. Br Med J (Clin Res Ed) 1981; 283:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/148\">",
"      Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009; 72:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/149\">",
"      Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009; 32:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/150\">",
"      Happe S, Kl&ouml;sch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology 2001; 57:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/151\">",
"      Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/152\">",
"      Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/153\">",
"      Hening WA, Walters A, Kavey N, et al. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology 1986; 36:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/154\">",
"      Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/155\">",
"      Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/156\">",
"      Garcia-Borreguero D, Larrosa O, Williams AM, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010; 74:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/157\">",
"      Telstad W, S&oslash;rensen O, Larsen S, et al. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) 1984; 288:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/158\">",
"      Wagner ML, Walters AS, Coleman RG, et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996; 19:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/159\">",
"      Derom E, Elinck W, Buylaert W, van der Straeten M. Which beta-blocker for the restless leg? Lancet 1984; 1:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/50/32554/abstract/160\">",
"      Evidente VG, Adler CH, Caviness JN, et al. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000; 15:324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4892 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32554=[""].join("\n");
var outline_f31_50_32554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary RLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary RLS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Venous insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other miscellaneous conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Periodic limb movements of sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Expert panel recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Intermittent RLS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Daily RLS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Refractory RLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102960355\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H102960405\">",
"      - Iron replacement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H102960441\">",
"      - Avoidance of aggravating drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H102960448\">",
"      - Short daily hemodialysis for patients in renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pramipexole and ropinirole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102960803\">",
"      Levodopa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H102960195\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Treatment in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9273048\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4892\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4892|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4711?source=related_link\">",
"      Nocturnal leg cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/9/15506?source=related_link\">",
"      Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/29/20946?source=related_link\">",
"      Patient information: Restless legs syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14773?source=related_link\">",
"      Uremic polyneuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_50_32555="Difficult patient characteristics";
var content_f31_50_32555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient characteristics that lead physicians to label them difficult",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients' expressions of emotion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients' personality/characterologic features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obsessive-compulsive; dependent; self-defeating; histrionic; narcissistic; paranoid; and schizoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients' personal characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Language and other communication barriers (deaf, blind); malodorous; communicable disease; racial/ethnic; impecunious; higher/lower social status; different sexual orientation from the doctor; and many other features that make the patient different from the doctor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients' specific clinical problems:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Somatization (including chronic pain); drug/alcohol abuse; psychiatric problems; sexual problems; organic mental syndromes; cancer; suicidal; difficult medical problem and getting worse; undiagnosed medical problem in spite of evaluation; noncompliance; giving bad news; death/dying; advance directives; and adverse health habits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patients' direct demands/stresses on the physician:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Threat of dismissal; patient disagrees with an explanation; patient complains (about care, the HMO); patient requires more time than available; seductive patient; aggressive or threatening patient; many legal/insurance papers to be filled out; unnecessary lab/referral/medication requests; unnecessary disability request; patient takes control of interaction; and patient wants social interaction or advice about nonmedical issues.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32555=[""].join("\n");
var outline_f31_50_32555=null;
var title_f31_50_32556="Malaria world epidemiology";
var content_f31_50_32556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Malaria cases in the world caused by",
"    <em>",
"     Plasmodium falciparum",
"    </em>",
"    and",
"    <em>",
"     Plasmodium vivax",
"    </em>",
"    , 2004-2005",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Region",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        <em>",
"         P. falciparum",
"        </em>",
"        in 2005",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        <em>",
"         P. vivax",
"        </em>",
"        in 2004",
"       </td>",
"       <td class=\"subtitle1\">",
"        <em>",
"         P. falciparum",
"        </em>",
"        plus",
"        <em>",
"         P. vivax",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Population at risk*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cases&bull;, no. (range); percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Population at risk*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cases&bull;, range (precent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cases&bull;, range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Africa",
"       </td>",
"       <td>",
"        521",
"       </td>",
"       <td>",
"        365 (215-374); 57",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        215-374",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Southeast Asia",
"       </td>",
"       <td>",
"        1314",
"       </td>",
"       <td>",
"        119 (66-224); 34",
"       </td>",
"       <td>",
"        1347",
"       </td>",
"       <td>",
"        90-248 (63)",
"       </td>",
"       <td>",
"        156-472",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Western Pacific",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        15 (9-26); 4",
"       </td>",
"       <td>",
"        890",
"       </td>",
"       <td>",
"        20-77 (20)",
"       </td>",
"       <td>",
"        29-103",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eastern Mediterranean",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        12 (5-25); 4",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        11-34 (9)",
"       </td>",
"       <td>",
"        16-59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Americas",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        4 (2-8); 1",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        10-28 (7)",
"       </td>",
"       <td>",
"        12-36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Europe",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1 (0-1); &lt;1",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1-4 (1)",
"       </td>",
"       <td>",
"        1-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        2212",
"       </td>",
"       <td>",
"        516 (297-658); 100",
"       </td>",
"       <td>",
"        2596",
"       </td>",
"       <td>",
"        132-391 (100)",
"       </td>",
"       <td>",
"        429-1049",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Expressed as millions of individuals.",
"     <br>",
"      &bull; Expressed as millions of cases.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Breman, JG, Plowe, C. A malaria vaccine for control: More progress. J Infect Dis 2009; 200:317. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32556=[""].join("\n");
var outline_f31_50_32556=null;
var title_f31_50_32557="Dapsone structure";
var content_f31_50_32557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Comparison of dapsone (a sulfone) and sulfonamide structures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dapsone is a sulfone medication, rather than a sulfonamide. Dapsone can cause hypersensitivity reactions that are clinically similar to those caused by sulfonamides, however.",
"    <br>",
"     <div class=\"footnotes\">",
"      * R: substituted aromatic ring.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32557=[""].join("\n");
var outline_f31_50_32557=null;
var title_f31_50_32558="Approach HCV child";
var content_f31_50_32558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Approach to treatment decisions for children with chronic hepatitis C virus (HCV) infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 417px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm outlines the author's recommendations for treatment for most children with HCV infection. Treatment decisions for individual patients may deviate from this algorithm because of parental preference and other complicating factors, including comorbid conditions that raise concerns for more rapid disease progression.",
"    <div class=\"footnotes\">",
"     PEG IFN: pegylated interferon alfa; HCV: hepatitis C virus.",
"     <br/>",
"     * In our practice, we are more likely to perform a liver biopsy for patients who have longer duration of disease (eg, children &gt;10 years old with perinatally acquired HCV) or for those with comorbid disease. Some providers perform liver biopsies only if the treatment decision is in question; others encourage liver biopsy to provide baseline information about disease severity.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If possible, treatment of children with HCV genotype 1 might be deferred until triple therapy is available for children, of done sooner in the context of a clinical trial.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32558=[""].join("\n");
var outline_f31_50_32558=null;
var title_f31_50_32559="Lymphoma bone CT";
var content_f31_50_32559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Primary lymphoma of bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This axial CT scan through the level of the distal femoral bones reveals a pattern of osteosclerosis in the involved right femur (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heather Pacholke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_50_32559=[""].join("\n");
var outline_f31_50_32559=null;
